{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:05:31Z","timestamp":1793142331220,"version":"4.5.0"},"reference-count":343,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The aim of the current review was to provide a new, in-depth insight into possible pharmacological targets of amantadine to pave the way to extending its therapeutic use to further indications beyond Parkinson\u2019s disease symptoms and viral infections. Considering amantadine\u2019s affinities in vitro and the expected concentration at targets at therapeutic doses in humans, the following primary targets seem to be most plausible: aromatic amino acids decarboxylase, glial-cell derived neurotrophic factor, sigma-1 receptors, phosphodiesterases, and nicotinic receptors. Further three targets could play a role to a lesser extent: NMDA receptors, 5-HT3 receptors, and potassium channels. Based on published clinical studies, traumatic brain injury, fatigue [e.g., in multiple sclerosis (MS)], and chorea in Huntington\u2019s disease should be regarded potential, encouraging indications. Preclinical investigations suggest amantadine\u2019s therapeutic potential in several further indications such as: depression, recovery after spinal cord injury, neuroprotection in MS, and cutaneous pain. Query in the database\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                    reveals research interest in several further indications: cancer, autism, cocaine abuse, MS, diabetes, attention deficit-hyperactivity disorder, obesity, and schizophrenia.\n                  <\/jats:p>","DOI":"10.1007\/s00702-021-02306-2","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T12:10:06Z","timestamp":1614082206000},"page":"127-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Amantadine: reappraisal of the timeless diamond\u2014target updates and novel therapeutic potentials"],"prefix":"10.1007","volume":"128","author":[{"given":"Wojciech","family":"Danysz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Dekundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Scheschonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Riederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"2306_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ibror.2018.12.001","volume":"6","author":"N Aboulghasemi","year":"2019","unstructured":"Aboulghasemi N, Hadipour Jahromy M, Ghasemi A (2019) Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model. IBRO Rep 6:40\u201344. https:\/\/doi.org\/10.1016\/j.ibror.2018.12.001","journal-title":"IBRO Rep"},{"key":"2306_CR2","unstructured":"Adamas (2020) Gocovri_Adamas. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208944lbl.pdf"},{"key":"2306_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/AJP.0000000000000547","volume":"34","author":"R Aiyer","year":"2018","unstructured":"Aiyer R, Mehta N, Gungor S, Gulati A (2018) A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice. Clin J Pain 34:450\u2013467. https:\/\/doi.org\/10.1097\/AJP.0000000000000547","journal-title":"Clin J Pain"},{"key":"2306_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5152\/TJAR.2018.20280","volume":"46","author":"EF Akcil","year":"2018","unstructured":"Akcil EF, Dilmen OK, Vehid H, Tunali Y (2018) Can amantadine ameliorate neurocognitive functions after subarachnoid haemorrhage? A Preliminary Study. Turk J Anaesthesiol Reanim 46:100\u2013107. https:\/\/doi.org\/10.5152\/TJAR.2018.20280","journal-title":"Turk J Anaesthesiol Reanim"},{"key":"2306_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0378-4274(98)00309-9","volume":"102\u2013103","author":"EX Albuquerque","year":"1998","unstructured":"Albuquerque EX, Pereira EF, Braga MF, Matsubayashi H, Alkondon M (1998) Neuronal nicotinic receptors modulate synaptic function in the hippocampus and are sensitive to blockade by the convulsant strychnine and by the anti-Parkinson drug amantadine. Toxicol Lett 102\u2013103:211\u2013218","journal-title":"Toxicol Lett"},{"key":"2306_CR6","first-page":"719","volume":"17","author":"RM Allen","year":"1982","unstructured":"Allen RM (1982) Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration. Biol Psychiatry 17:719\u2013727","journal-title":"Biol Psychiatry"},{"issue":"Suppl 1","key":"2306_CR7","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1097\/00002826-198300061-00009","volume":"6","author":"RM Allen","year":"1983","unstructured":"Allen RM (1983) Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology. Clin Neuropharmacol 6(Suppl 1):S64-73. https:\/\/doi.org\/10.1097\/00002826-198300061-00009","journal-title":"Clin Neuropharmacol"},{"key":"2306_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0014-2999(80)90409-4","volume":"65","author":"RM Allen","year":"1980","unstructured":"Allen RM, Lane JD, Brauchi JT (1980) Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum. Eur J Pharmacol 65:313\u2013315. https:\/\/doi.org\/10.1016\/0014-2999(80)90409-4","journal-title":"Eur J Pharmacol"},{"key":"2306_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","volume":"138","author":"SJ Allen","year":"2013","unstructured":"Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther 138:155\u2013175. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.01.004","journal-title":"Pharmacol Ther"},{"key":"2306_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.expneurol.2004.08.030","volume":"191","author":"KA Allers","year":"2005","unstructured":"Allers KA, Bergstrom DA, Ghazi LJ, Kreiss DS, Walters JR (2005) MK801 and amantadine exert different effects on subthalamic neuronal activity in a rodent model of Parkinson\u2019s disease. Exp Neurol 191:104\u2013118. https:\/\/doi.org\/10.1016\/j.expneurol.2004.08.030","journal-title":"Exp Neurol"},{"key":"2306_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1046\/j.1464-5491.2003.00882.x","volume":"20","author":"P Amin","year":"2003","unstructured":"Amin P, Sturrock ND (2003) A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabet Med 20:114\u2013118","journal-title":"Diabet Med"},{"key":"2306_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1590\/0004-282X20170196","volume":"76","author":"R Anghinah","year":"2018","unstructured":"Anghinah R, Amorim RLO, Paiva WS, Schmidt MT, Ianof JN (2018) Traumatic brain injury pharmacological treatment: recommendations. Arq Neuropsiquiatr 76:100\u2013103. https:\/\/doi.org\/10.1590\/0004-282X20170196","journal-title":"Arq Neuropsiquiatr"},{"key":"2306_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","volume":"17","author":"S Angus","year":"1997","unstructured":"Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM (1997) A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 17:88\u201391","journal-title":"J Clin Psychopharmacol"},{"key":"2306_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/00003088-198814010-00003","volume":"14","author":"FY Aoki","year":"1988","unstructured":"Aoki FY, Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14:35\u201351","journal-title":"Clin Pharmacokinet"},{"key":"2306_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/cpt1979266729","volume":"26","author":"FY Aoki","year":"1979","unstructured":"Aoki FY, Sitar DS, Ogilvie RI (1979) Amantadine kinetics in healthy young subjects after long-term dosing. Clin Pharmacol Ther 26:729\u2013736","journal-title":"Clin Pharmacol Ther"},{"key":"2306_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0006-8993(03)02531-9","volume":"972","author":"A Arai","year":"2003","unstructured":"Arai A, Kannari K, Shen H, Maeda T, Suda T, Matsunaga M (2003) Amantadine increases l-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats. Brain Res 972:229\u2013234","journal-title":"Brain Res"},{"key":"2306_CR17","doi-asserted-by":"publisher","first-page":"109755","DOI":"10.1016\/j.mehy.2020.109755","volume":"140","author":"GEA Aranda-Abreu","year":"2020","unstructured":"Aranda-Abreu GEA, Aguilar MEH, Covarrubias DH, Duran FR (2020c) Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses 140:109755. https:\/\/doi.org\/10.1016\/j.mehy.2020.109755","journal-title":"Med Hypotheses"},{"key":"2306_CR18","doi-asserted-by":"crossref","unstructured":"Aranda-Abreu GE, Aranda-Mart\u00ednez JD, Ara\u00fajo R (2020a) Amantadine for the treatment of SARS-Cov-2: case report. J Pharm Pharmacol 8(1):2","DOI":"10.13188\/2327-204X.S200006"},{"key":"2306_CR19","doi-asserted-by":"crossref","unstructured":"Aranda-Abreu GE, Hern\u00e1ndez-Aguilar ME, Herrera-Covarrubias D, Rojas-Dur\u00e1n F (2020b) The Sars-Cov-2 viroporin e and its interaction with amantadine an analysis. J Pharm Pharmacol 8(1):2","DOI":"10.13188\/2327-204X.S200003"},{"key":"2306_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM, American Academy of N (2012) Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 79:597\u2013603. https:\/\/doi.org\/10.1212\/WNL.0b013e318263c443","journal-title":"Neurology"},{"key":"2306_CR21","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/0006-2952(80)90292-0","volume":"29","author":"RS Aronstam","year":"1980","unstructured":"Aronstam RS, Eldefrawi AT, Eldefrawi ME (1980) Similarities in the binding sites of the muscarinic receptor and the ionic channel of the nicotinic receptor. Biochem Pharmacol 29:1311\u20131314","journal-title":"Biochem Pharmacol"},{"key":"2306_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1476-5381.1991.tb12472.x","volume":"104","author":"FM Ashcroft","year":"1991","unstructured":"Ashcroft FM, Kerr AJ, Gibson JS, Williams BA (1991) Amantadine and sparteine inhibit ATP-regulated K-currents in the insulin-secreting beta-cell line, HIT-T15. Br J Pharmacol 104:579\u2013584. https:\/\/doi.org\/10.1111\/j.1476-5381.1991.tb12472.x","journal-title":"Br J Pharmacol"},{"key":"2306_CR23","first-page":"428","volume":"43","author":"F Ashtari","year":"2009","unstructured":"Ashtari F, Fatehi F, Shaygannejad V, Chitsaz A (2009) Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis? Neurol Neurochir Pol 43:428\u2013432","journal-title":"Neurol Neurochir Pol"},{"key":"2306_CR24","first-page":"246","volume":"216","author":"EV Bailey","year":"1975","unstructured":"Bailey EV, Stone TW (1975) The mechanism of amantadine in Parkinsonism: a review. Arch Int Pharmacodyn Ther 216:246\u2013262","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2306_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0006-2952(72)90252-3","volume":"21","author":"RJ Baldessarini","year":"1972","unstructured":"Baldessarini RJ, Lipinski JF, Chace KV (1972) Effects of amantadine hydrochloride on catecholamine metabolism in the brain of the rat. Biochem Pharmacol 21:77\u201387. https:\/\/doi.org\/10.1016\/0006-2952(72)90252-3","journal-title":"Biochem Pharmacol"},{"key":"2306_CR26","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.neubiorev.2009.03.011","volume":"33","author":"JW Bales","year":"2009","unstructured":"Bales JW, Wagner AK, Kline AE, Dixon CE (2009) Persistent cognitive dysfunction after traumatic brain injury: a dopamine hypothesis. Neurosci Biobehav Rev 33:981\u20131003. https:\/\/doi.org\/10.1016\/j.neubiorev.2009.03.011","journal-title":"Neurosci Biobehav Rev"},{"key":"2306_CR27","first-page":"212","volume":"53","author":"S Balogh","year":"1992","unstructured":"Balogh S, Hendricks SE, Kang J (1992) Treatment of fluoxetine-induced anorgasmia with amantadine. J Clin Psychiatry 53:212\u2013213","journal-title":"J Clin Psychiatry"},{"key":"2306_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/00926239608404410","volume":"22","author":"R Balon","year":"1996","unstructured":"Balon R (1996) Intermittent amantadine for fluoxetine-induced anorgasmia. J Sex Marit Ther 22:290\u2013292","journal-title":"J Sex Marit Ther"},{"key":"2306_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/s-2007-979482","volume":"30","author":"T Baptista","year":"1997","unstructured":"Baptista T et al (1997) Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. Pharmacopsychiatry 30:43\u201354","journal-title":"Pharmacopsychiatry"},{"key":"2306_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/PHM.0b013e31811473b3","volume":"86","author":"AM Barrett","year":"2007","unstructured":"Barrett AM, Eslinger PJ (2007) Amantadine for adynamic speech: possible benefit for aphasia? Am J Phys Med Rehabil 86:605\u2013612. https:\/\/doi.org\/10.1097\/PHM.0b013e31811473b3","journal-title":"Am J Phys Med Rehabil"},{"key":"2306_CR31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/00001199-200509000-00006","volume":"20","author":"SR Beers","year":"2005","unstructured":"Beers SR, Skold A, Dixon CE, Adelson PD (2005) Neurobehavioral effects of amantadine after pediatric traumatic brain injury: a preliminary report. J Head Trauma Rehabil 20:450\u2013463. https:\/\/doi.org\/10.1097\/00001199-200509000-00006","journal-title":"J Head Trauma Rehabil"},{"key":"2306_CR32","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4155\/fmc.10.179","volume":"2","author":"G Bhave","year":"2010","unstructured":"Bhave G, Lonergan D, Chauder BA, Denton JS (2010) Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities. Future Med Chem 2:757\u2013774. https:\/\/doi.org\/10.4155\/fmc.10.179","journal-title":"Future Med Chem"},{"key":"2306_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","volume":"81","author":"R Bhidayasiri","year":"2013","unstructured":"Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA, American Academy of N (2013) Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 81:463\u2013469. https:\/\/doi.org\/10.1212\/WNL.0b013e31829d86b6","journal-title":"Neurology"},{"key":"2306_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","volume":"389","author":"R Bhidayasiri","year":"2018","unstructured":"Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S (2018) Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci 389:67\u201375. https:\/\/doi.org\/10.1016\/j.jns.2018.02.010","journal-title":"J Neurol Sci"},{"key":"2306_CR35","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/mt.2010.107","volume":"18","author":"K Biju","year":"2010","unstructured":"Biju K et al (2010) Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson\u2019s disease. Mol Ther 18:1536\u20131544. https:\/\/doi.org\/10.1038\/mt.2010.107","journal-title":"Mol Ther"},{"key":"2306_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1152\/jn.1997.77.1.309","volume":"77","author":"TA Blanpied","year":"1997","unstructured":"Blanpied TA, Boeckman FA, Aizenman E, Johnson JW (1997) Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 77:309\u2013323","journal-title":"J Neurophysiol"},{"key":"2306_CR37","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1523\/JNEUROSCI.4262-04.2005","volume":"25","author":"TA Blanpied","year":"2005","unstructured":"Blanpied TA, Clarke RJ, Johnson JW (2005) Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 25:3312\u20133322","journal-title":"J Neurosci"},{"key":"2306_CR38","first-page":"484","volume":"150","author":"WE Bleidner","year":"1965","unstructured":"Bleidner WE, Harmon JB, Hewes WE, Lynes TE, Hermann EC (1965) Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 150:484\u2013490","journal-title":"J Pharmacol Exp Ther"},{"key":"2306_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.brainres.2019.03.007","volume":"1714","author":"IH Bleimeister","year":"2019","unstructured":"Bleimeister IH et al (2019) Environmental enrichment and amantadine confer individual but nonadditive enhancements in motor and spatial learning after controlled cortical impact injury. Brain Res 1714:227\u2013233. https:\/\/doi.org\/10.1016\/j.brainres.2019.03.007","journal-title":"Brain Res"},{"key":"2306_CR40","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0140-6736(05)60979-8","volume":"349","author":"L Bode","year":"1997","unstructured":"Bode L, Dietrich DE, Stoyloff R, Emrich HM, Ludwig H (1997) Amantadine and human borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet 349:178\u2013179","journal-title":"Lancet"},{"key":"2306_CR41","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1124\/jpet.109.162396","volume":"333","author":"T Bordia","year":"2010","unstructured":"Bordia T, Campos C, McIntosh JM, Quik M (2010) Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther 333:929\u2013938. https:\/\/doi.org\/10.1124\/jpet.109.162396","journal-title":"J Pharmacol Exp Ther"},{"key":"2306_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1212\/wnl.39.5.749-b","volume":"39","author":"MI Botez","year":"1989","unstructured":"Botez MI, Young SN, Rotez T, Courchesne Y (1989) Treatment of Friedreich\u2019s ataxia with amantadine. Neurology 39:749\u2013750. https:\/\/doi.org\/10.1212\/wnl.39.5.749-b","journal-title":"Neurology"},{"key":"2306_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/jnnp.61.3.259","volume":"61","author":"MI Botez","year":"1996","unstructured":"Botez MI, Botezmarquard T, Elie R, Pedraza OL, Goyette K, Lalonde R (1996) Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. J Neurol Neurosurg Psychiatry 61:259\u2013264","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2306_CR44","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1002\/jmv.26030","volume":"92","author":"SR Brenner","year":"2020","unstructured":"Brenner SR (2020) The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. J Med Virol 92:2341\u20132342. https:\/\/doi.org\/10.1002\/jmv.26030","journal-title":"J Med Virol"},{"key":"2306_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00314331","volume":"236","author":"M Brenner","year":"1989","unstructured":"Brenner M, Haass A, Jacobi P, Schimrigk K (1989) Amantadine sulphate in treating Parkinson\u2019s disease: clinical effects, psychometric tests and serum concentrations. J Neurol 236:153\u2013156","journal-title":"J Neurol"},{"key":"2306_CR46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/0028-3908(95)00017-Z","volume":"34","author":"I Bresink","year":"1995","unstructured":"Bresink I, Danysz W, Parsons CG, Mutschler E (1995) Different binding affinities of NMDA receptor channel blockers in various brain regions\u2014indication of NMDA receptor heterogeneity. Neuropharmacology 34:533\u2013540","journal-title":"Neuropharmacology"},{"key":"2306_CR47","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1124\/jpet.118.247650","volume":"367","author":"EF Brigham","year":"2018","unstructured":"Brigham EF et al (2018) Pharmacokinetic\/pharmacodynamic correlation analysis of amantadine for levodopa-induced dyskinesia. J Pharmacol Exp Ther 367:373\u2013381. https:\/\/doi.org\/10.1124\/jpet.118.247650","journal-title":"J Pharmacol Exp Ther"},{"key":"2306_CR48","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1128\/JVI.02972-13","volume":"88","author":"E Brison","year":"2014","unstructured":"Brison E, Jacomy H, Desforges M, Talbot PJ (2014) Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus. J Virol 88:1548\u20131563. https:\/\/doi.org\/10.1128\/JVI.02972-13","journal-title":"J Virol"},{"key":"2306_CR49","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1476-5381.1976.tb08624.x","volume":"58","author":"F Brown","year":"1976","unstructured":"Brown F, Redfern PH (1976) Studies on the mechanism of action of amantadine. Br J Pharmacol 58:561\u2013567. https:\/\/doi.org\/10.1111\/j.1476-5381.1976.tb08624.x","journal-title":"Br J Pharmacol"},{"key":"2306_CR50","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/cne.21647","volume":"507","author":"JA Buckwalter","year":"2008","unstructured":"Buckwalter JA, Parvizi J, Morecraft RJ, van Hoesen GW (2008) Thalamic projections to the posteromedial cortex in the macaque. J Comp Neurol 507:1709\u20131733. https:\/\/doi.org\/10.1002\/cne.21647","journal-title":"J Comp Neurol"},{"key":"2306_CR51","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1124\/mol.53.3.555","volume":"53","author":"B Buisson","year":"1998","unstructured":"Buisson B, Bertrand D (1998) Open-channel blockers at the human alpha 4 beta 2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:555\u2013563","journal-title":"Mol Pharmacol"},{"key":"2306_CR52","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/mol.54.2.342","volume":"54","author":"AE Busch","year":"1998","unstructured":"Busch AE et al (1998) Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54:342\u2013352","journal-title":"Mol Pharmacol"},{"key":"2306_CR53","first-page":"1","volume":"3","author":"RF Butterworth","year":"2020","unstructured":"Butterworth RF (2020a) Amantadine for the treatment of traumatic brain injury and its associated cognitive and neurobehavioural complications. J Pharmacol Pharm Res 3:1\u20135","journal-title":"J Pharmacol Pharm Res"},{"key":"2306_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.13188\/2376-922X.1000030","volume":"7","author":"RF Butterworth","year":"2020","unstructured":"Butterworth RF (2020b) Amantadine treatment for Parkinson\u2019s disease during COVID-19: bimodal action targeting viral replication and the NMDA receptor. J Parkinsons Dis Alzheimer Dis 7:1\u20134","journal-title":"J Parkinsons Dis Alzheimer Dis"},{"key":"2306_CR55","first-page":"1","volume":"2020","author":"RF Butterworth","year":"2020","unstructured":"Butterworth RF (2020c) Amantadine, Parkinson\u2019s disease and COVID-19. Covid Perspect Res Rev 2020:1\u20136","journal-title":"Covid Perspect Res Rev"},{"key":"2306_CR56","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neulet.2005.10.027","volume":"394","author":"AS Caumont","year":"2006","unstructured":"Caumont AS, Octave JN, Hermans E (2006) Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. Neurosci Lett 394:196\u2013201","journal-title":"Neurosci Lett"},{"key":"2306_CR57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1471-4159.1988.tb01062.x","volume":"51","author":"JJ Cha","year":"1988","unstructured":"Cha JJ, Greenamyre JT, Nielsen EO, Penney JB, Young AB (1988) Properties of quisqualate-sensitive L-[3H]glutamate binding sites in rat brain as determined by quantitative autoradiography. J Neurochem 51:469\u2013478","journal-title":"J Neurochem"},{"key":"2306_CR58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/02699058809150901","volume":"2","author":"MC Chandler","year":"1988","unstructured":"Chandler MC, Barnhill JL, Gualtieri CT (1988) Amantadine for the agitated head-injury patient. Brain Inj 2:309\u2013311. https:\/\/doi.org\/10.3109\/02699058809150901","journal-title":"Brain Inj"},{"key":"2306_CR59","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1523\/JNEUROSCI.12-11-04427.1992","volume":"12","author":"HSV Chen","year":"1992","unstructured":"Chen HSV, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine\u2014therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12:4427\u20134436","journal-title":"J Neurosci"},{"key":"2306_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2012.07.037","volume":"693","author":"YW Chen","year":"2012","unstructured":"Chen YW, Shieh JP, Chen YC, Leung YM, Hung CH, Wang JJ (2012) Cutaneous analgesia after subcutaneous injection of memantine and amantadine and their systemic toxicity in rats. Eur J Pharmacol 693:25\u201330. https:\/\/doi.org\/10.1016\/j.ejphar.2012.07.037","journal-title":"Eur J Pharmacol"},{"key":"2306_CR61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.expneurol.2018.07.017","volume":"309","author":"S Cheng","year":"2018","unstructured":"Cheng S et al (2018) Therapeutic efficacy of regulable GDNF expression for Huntington\u2019s and Parkinson\u2019s disease by a high-induction, background-free \u201cGeneSwitch\u201d vector. Exp Neurol 309:79\u201390. https:\/\/doi.org\/10.1016\/j.expneurol.2018.07.017","journal-title":"Exp Neurol"},{"key":"2306_CR62","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1017\/S0317167100042360","volume":"19","author":"S Chiba","year":"1992","unstructured":"Chiba S, Ito M, Matsumoto H (1992) Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis. Can J Neurol Sci 19:309","journal-title":"Can J Neurol Sci"},{"key":"2306_CR63","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/archneur.1989.00520420096030","volume":"46","author":"RA Cohen","year":"1989","unstructured":"Cohen RA, Fisher M (1989) Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 46:676\u2013680. https:\/\/doi.org\/10.1001\/archneur.1989.00520420096030","journal-title":"Arch Neurol"},{"key":"2306_CR64","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/1352458518754716","volume":"25","author":"JA Cohen","year":"2019","unstructured":"Cohen JA et al (2019) Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: a randomized, placebo-controlled, phase 2 trial. Mult Scler 25:601\u2013609. https:\/\/doi.org\/10.1177\/1352458518754716","journal-title":"Mult Scler"},{"key":"2306_CR65","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1056\/NEJMoa2001017","volume":"54","author":"A Cortes Borra","year":"2020","unstructured":"Cortes Borra A (2020) Does amantadine have a protective effect against COVID-19? Neurol Neurochir Pol 54:284\u2013285. https:\/\/doi.org\/10.1056\/NEJMoa2001017","journal-title":"Neurol Neurochir Pol"},{"key":"2306_CR66","first-page":"209","volume":"9","author":"GE Crane","year":"1968","unstructured":"Crane GE (1968) Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie 9:209\u2013218","journal-title":"Agressologie"},{"key":"2306_CR67","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1056\/NEJM197111112852025","volume":"285","author":"GE Crane","year":"1971","unstructured":"Crane GE (1971) More on amantadine in tardive dyskinesia. N Engl J Med 285:1150\u20131151","journal-title":"N Engl J Med"},{"key":"2306_CR68","doi-asserted-by":"publisher","unstructured":"Crosby NJ, Deane KH, Clarke CE (2003) Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003467","DOI":"10.1002\/14651858.CD003467"},{"key":"2306_CR69","first-page":"2035","volume":"142","author":"B Cubitt","year":"1997","unstructured":"Cubitt B, delaTorre JC (1997) Amantadine does not have antiviral activity against Borna disease virus. ArchVirol 142:2035\u20132042","journal-title":"ArchVirol"},{"key":"2306_CR70","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/sj.bjp.0704319","volume":"134","author":"WA Daniel","year":"2001","unstructured":"Daniel WA, Wojcikowski J, Palucha A (2001) Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. Br J Pharmacol 134:807\u2013814. https:\/\/doi.org\/10.1038\/sj.bjp.0704319","journal-title":"Br J Pharmacol"},{"key":"2306_CR71","first-page":"1278","volume":"24","author":"W Danielczyk","year":"1973","unstructured":"Danielczyk W (1973) Therapy of akinetic crises. Med Welt 24:1278\u20131282","journal-title":"Med Welt"},{"issue":"Suppl.","key":"2306_CR72","first-page":"399","volume":"46","author":"W Danielczyk","year":"1995","unstructured":"Danielczyk W (1995) Twenty-five years of amantadine therapy in Parkinson\u2019s disease. J Neural Transm 46(Suppl.):399\u2013405","journal-title":"J Neural Transm"},{"key":"2306_CR73","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0091-3057(94)90506-1","volume":"48","author":"W Danysz","year":"1994","unstructured":"Danysz W, Essmann U, Bresink I, Wilke R (1994a) Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 48:111\u2013118","journal-title":"Pharmacol Biochem Behav"},{"key":"2306_CR74","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/BF02253435","volume":"7","author":"W Danysz","year":"1994","unstructured":"Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G (1994b) Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J Neural Transm Parkinsons Dis Dement Sect 7:155\u2013166","journal-title":"J Neural Transm Parkinsons Dis Dement Sect"},{"key":"2306_CR75","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0149-7634(96)00037-1","volume":"21","author":"W Danysz","year":"1997","unstructured":"Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents\u2014preclinical studies. Neurosci Biobehav Rev 21:455\u2013468","journal-title":"Neurosci Biobehav Rev"},{"key":"2306_CR76","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1126\/science.144.3620.862","volume":"144","author":"WL Davies","year":"1964","unstructured":"Davies WL et al (1964) Antiviral activity of 1-adamantanamine (amantadine). Science 144:862\u2013863. https:\/\/doi.org\/10.1126\/science.144.3620.862","journal-title":"Science"},{"key":"2306_CR77","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.euroneuro.2004.03.005","volume":"15","author":"W Deberdt","year":"2005","unstructured":"Deberdt W et al (2005) Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 15:13\u201321. https:\/\/doi.org\/10.1016\/j.euroneuro.2004.03.005","journal-title":"Eur Neuropsychopharmacol"},{"key":"2306_CR78","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1056\/NEJM197110072851516","volume":"285","author":"BL Decker","year":"1971","unstructured":"Decker BL, Davis JM, Jonowsky DS, el-Yousef MK, Sekerke HJ (1971) Amantadine hydrochloride treatment of tardive dyskinesia. N Engl J Med 285:860. https:\/\/doi.org\/10.1056\/NEJM197110072851516","journal-title":"N Engl J Med"},{"key":"2306_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0006-8993(94)01294-R","volume":"671","author":"MA Decoster","year":"1995","unstructured":"Decoster MA, Klette KL, Knight ES, Tortella FC (1995) sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 671:45\u201353","journal-title":"Brain Res"},{"key":"2306_CR80","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/(SICI)1098-2396(19991215)34:4<313::AID-SYN7>3.0.CO;2-1","volume":"34","author":"P Deep","year":"1999","unstructured":"Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P (1999) Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 34:313\u2013318","journal-title":"Synapse"},{"key":"2306_CR81","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76\u201389","journal-title":"Behav Brain Res"},{"key":"2306_CR82","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1017\/s0317167100016826","volume":"32","author":"R DeMarchi","year":"2005","unstructured":"DeMarchi R, Bansal V, Hung A, Wroblewski K, Dua H, Sockalingam S, Bhalerao S (2005) Review of awakening agents. Can J Neurol Sci 32:4\u201317. https:\/\/doi.org\/10.1017\/s0317167100016826","journal-title":"Can J Neurol Sci"},{"key":"2306_CR84","unstructured":"Demisch L (1988) Pilotuntersuchungen zum Einflub von Amantadine, Memantine und Deprenyl auf MAO Typ A und B Aktivit\u00e4t und den Serotonintransport (unpublished report)"},{"key":"2306_CR85","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40120-019-0144-1","volume":"8","author":"T deVries","year":"2019","unstructured":"deVries T, Dentiste A, Handiwala L, Jacobs D (2019) Bioavailability and pharmacokinetics of once-daily amantadine extended-release tablets in healthy volunteers: results from three randomized, crossover, open-label, phase 1 studies. Neurol Ther 8:449\u2013460. https:\/\/doi.org\/10.1007\/s40120-019-0144-1","journal-title":"Neurol Ther"},{"key":"2306_CR86","first-page":"276","volume":"217","author":"KM Dhasmana","year":"1975","unstructured":"Dhasmana KM (1975) Effect of amantadine on blood pressure responses induced by vagal and sympathetic stimulation. Arch Int Pharmacodyn Ther 217:276\u2013279","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2306_CR87","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1034\/j.1399-5618.2000.020110.x","volume":"2","author":"DE Dietrich","year":"2000","unstructured":"Dietrich DE et al (2000) Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord 2:65\u201370. https:\/\/doi.org\/10.1034\/j.1399-5618.2000.020110.x","journal-title":"Bipolar Disord"},{"key":"2306_CR88","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tips.2014.12.002","volume":"36","author":"KT Dineley","year":"2015","unstructured":"Dineley KT, Pandya AA, Yakel JL (2015) Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci 36:96\u2013108. https:\/\/doi.org\/10.1016\/j.tips.2014.12.002","journal-title":"Trends Pharmacol Sci"},{"key":"2306_CR89","first-page":"285","volume":"14","author":"CE Dixon","year":"1999","unstructured":"Dixon CE et al (1999) Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats. Restor Neurol Neurosci 14:285\u2013294","journal-title":"Restor Neurol Neurosci"},{"key":"2306_CR90","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5137\/1019-5149.JTN.26801-19.3","volume":"30","author":"G Dogan","year":"2020","unstructured":"Dogan G, Karaca O (2020) N-methyl-d-aspartate receptor antagonists may ameliorate spinal cord injury by inhibiting oxidative stress: an experimental study in rats. Turk Neurosurg 30:60\u201368. https:\/\/doi.org\/10.5137\/1019-5149.JTN.26801-19.3","journal-title":"Turk Neurosurg"},{"key":"2306_CR91","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10571-015-0244-0","volume":"36","author":"H Dong","year":"2016","unstructured":"Dong H, Ma Y, Ren Z, Xu B, Zhang Y, Chen J, Yang B (2016) Sigma-1 receptor modulates neuroinflammation after traumatic brain injury. Cell Mol Neurobiol 36:639\u2013645. https:\/\/doi.org\/10.1007\/s10571-015-0244-0","journal-title":"Cell Mol Neurobiol"},{"key":"2306_CR92","first-page":"353","volume":"38","author":"JP Dunn","year":"1986","unstructured":"Dunn JP, Henkel JG, Gianutsos G (1986) Pharmacological activity of amantadine: effect of N-alkyl substitution. JPharmPharmacol 38:353\u2013356","journal-title":"JPharmPharmacol"},{"key":"2306_CR93","first-page":"703","volume":"54","author":"M Dziedzicka-Wasylewska","year":"2002","unstructured":"Dziedzicka-Wasylewska M, Rogoz Z, Solich J, Dudek D, Wrobel A, Zieba A (2002) Effect of joint administration of imipramine and amantadine on binding of [3H]7-OH-DPAT to dopamine D3 receptors in peripheral blood lymphocytes of the patients with drug-resistant unipolar depression. Pol J Pharmacol 54:703\u2013706","journal-title":"Pol J Pharmacol"},{"key":"2306_CR94","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpain.2006.08.003","volume":"8","author":"E Eisenberg","year":"2007","unstructured":"Eisenberg E, Pud D, Koltun L, Loven D (2007) Effect of early administration of the N-methyl-d-aspartate receptor antagonist amantadine on the development of postmastectomy pain syndrome: a prospective pilot study. J Pain 8:223\u2013229. https:\/\/doi.org\/10.1016\/j.jpain.2006.08.003","journal-title":"J Pain"},{"key":"2306_CR95","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/0035-9203(94)90229-1","volume":"88","author":"SG Evans","year":"1994","unstructured":"Evans SG, Havlik I (1994) In vitro drug interaction between amantadine and classical antimalarial drugs in plasmodium falciparum infections. Trans R Soc Trop Med Hyg 88:683\u2013686","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2306_CR96","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/0024-3205(85)90004-9","volume":"37","author":"M Fayez","year":"1985","unstructured":"Fayez M, Ahmed HH, Quadri SK (1985) Inhibition of plasma prolactin in the rat by amantadine. Life Sci 37:1877\u20131880. https:\/\/doi.org\/10.1016\/0024-3205(85)90004-9","journal-title":"Life Sci"},{"key":"2306_CR97","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/0091-3057(95)00011-K","volume":"51","author":"MR Ferraz","year":"1995","unstructured":"Ferraz MR, Santos R (1995) Amantadine stimulates sexual behavior in male rats. Pharmacol Biochem Behav 51:709\u2013714","journal-title":"Pharmacol Biochem Behav"},{"key":"2306_CR98","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1055\/s-2007-979220","volume":"32","author":"R Ferszt","year":"1999","unstructured":"Ferszt R et al (1999) Amantadine revisited: An open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection. Pharmacopsychiatry 32:142\u2013147","journal-title":"Pharmacopsychiatry"},{"key":"2306_CR99","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fnbeh.2011.00071","volume":"5","author":"M Feyder","year":"2011","unstructured":"Feyder M, Bonito-Oliva A, Fisone G (2011) l-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci 5:71. https:\/\/doi.org\/10.3389\/fnbeh.2011.00071","journal-title":"Front Behav Neurosci"},{"key":"2306_CR100","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1017\/s0317167100047417","volume":"20","author":"A Filla","year":"1993","unstructured":"Filla A et al (1993) A double-blind cross-over trial of amantadine hydrochloride in Friedreich\u2019s ataxia. Can J Neurol Sci 20:52\u201355. https:\/\/doi.org\/10.1017\/s0317167100047417","journal-title":"Can J Neurol Sci"},{"key":"2306_CR101","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF01345241","volume":"14","author":"A Fisher","year":"1998","unstructured":"Fisher A, Biggs CS, Starr MS (1998) Effects of glutamate antagonists on the activity of aromatic l-amino acid decarboxylase. Amino Acids 14:43\u201349","journal-title":"Amino Acids"},{"key":"2306_CR102","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.4103\/1673-5374.145351","volume":"9","author":"V Francardo","year":"2014","unstructured":"Francardo V (2014) Sigma-1 receptor: a potential new target for Parkinson\u2019s disease? Neural Regener Res 9:1882\u20131883. https:\/\/doi.org\/10.4103\/1673-5374.145351","journal-title":"Neural Regener Res"},{"key":"2306_CR103","first-page":"173","volume":"56","author":"O Freudenreich","year":"1995","unstructured":"Freudenreich O, McEvoy JP (1995) Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics [letter]. J Clin Psychiatry 56:173","journal-title":"J Clin Psychiatry"},{"key":"2306_CR104","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/ncn3.12342","volume":"8","author":"Y Fukumoto","year":"2019","unstructured":"Fukumoto Y, Miyamoto K, Moriguchi K, Kusunoki S (2019) Amantadine regulates the severity of experimental autoimmune encephalomyelitis. Neurol Clin Neurosci 8:11\u201315. https:\/\/doi.org\/10.1111\/ncn3.12342","journal-title":"Neurol Clin Neurosci"},{"key":"2306_CR105","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/bmj.4.5894.693","volume":"4","author":"AW Galbraith","year":"1973","unstructured":"Galbraith AW (1973) Treatment of acute herpes zoster with amantadine hydrochloride (Symmetrel). Br Med J 4:693\u2013695. https:\/\/doi.org\/10.1136\/bmj.4.5894.693","journal-title":"Br Med J"},{"key":"2306_CR106","doi-asserted-by":"publisher","first-page":"e21822","DOI":"10.1097\/MD.0000000000021822","volume":"99","author":"Y Gao","year":"2020","unstructured":"Gao Y, Zhang Y, Li Z, Ma L, Yang J (2020a) Persistent vegetative state after severe cerebral hemorrhage treated with amantadine: a retrospective controlled study. Medicine (Baltimore) 99:e21822. https:\/\/doi.org\/10.1097\/MD.0000000000021822","journal-title":"Medicine (Baltimore)"},{"key":"2306_CR107","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1080\/02699052.2020.1780315","volume":"34","author":"Y Gao","year":"2020","unstructured":"Gao Y, Ma L, Liang F, Zhang Y, Yang L, Liu X, Yang J (2020b) The use of amantadine in patients with unresponsive wakefulness syndrome after severe cerebral hemorrhage. Brain Inj 34:1084\u20131088. https:\/\/doi.org\/10.1080\/02699052.2020.1780315","journal-title":"Brain Inj"},{"key":"2306_CR108","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/archneur.1996.00550020101021","volume":"53","author":"MW Geisler","year":"1996","unstructured":"Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB (1996) The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 53:185\u2013188","journal-title":"Arch Neurol"},{"key":"2306_CR109","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1310\/hpj4908-710","volume":"49","author":"JA Generali","year":"2014","unstructured":"Generali JA, Cada DJ (2014) Amantadine: multiple sclerosis-related fatigue. Hosp Pharm 49:710\u2013712. https:\/\/doi.org\/10.1310\/hpj4908-710","journal-title":"Hosp Pharm"},{"key":"2306_CR110","first-page":"760","volume":"6","author":"K Gerzon","year":"1963","unstructured":"Gerzon K, Krumkalns EV, Brindle RL, Marshall FJ, Root MA (1963) The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N\u2032-adamantylureas. JMedChem 6:760\u2013763","journal-title":"JMedChem"},{"key":"2306_CR111","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1080\/02699052.2018.1476733","volume":"32","author":"H Ghalaenovi","year":"2018","unstructured":"Ghalaenovi H et al (2018) The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial. Brain Inj 32:1050\u20131055. https:\/\/doi.org\/10.1080\/02699052.2018.1476733","journal-title":"Brain Inj"},{"key":"2306_CR112","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1102609","volume":"366","author":"JT Giacino","year":"2012","unstructured":"Giacino JT et al (2012) Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 366:819\u2013826. https:\/\/doi.org\/10.1056\/NEJMoa1102609","journal-title":"N Engl J Med"},{"key":"2306_CR113","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.apmr.2018.07.001","volume":"99","author":"JT Giacino","year":"2018","unstructured":"Giacino JT et al (2018) Practice guideline update recommendations summary: disorders of consciousness: report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability Independent, Living, and Rehabilitation Research. Arch Phys Med Rehabil 99:1699\u20131709. https:\/\/doi.org\/10.1016\/j.apmr.2018.07.001","journal-title":"Arch Phys Med Rehabil"},{"key":"2306_CR114","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0014-2999(85)90564-3","volume":"110","author":"G Gianutsos","year":"1985","unstructured":"Gianutsos G, Chute S, Dunn JP (1985) Pharmacological changes in dopaminergic systems induced by long term administration of amantadine. Eur J Pharmacol 110:357\u2013361","journal-title":"Eur J Pharmacol"},{"key":"2306_CR115","first-page":"124","volume":"56","author":"MJ Gitlin","year":"1995","unstructured":"Gitlin MJ (1995) Treatment of sexual side effects with dopaminergic agents [4]. J Clin Psychiatry 56:124","journal-title":"J Clin Psychiatry"},{"key":"2306_CR116","first-page":"16","volume":"63","author":"VE Gmiro","year":"2000","unstructured":"Gmiro VE, Serdiuk SE (2000) A comparative study of the central H-cholinergic-blocking and NMDA-blocking actions of MK-801, memantin, amantadine, pyrilen and IEM-1754 in experiments on intact rats. Eksperimental\u2019naia i klinicheskaia farmakologiia 63:16\u201320","journal-title":"Eksperimental'naia i klinicheskaia farmakologiia"},{"key":"2306_CR117","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/0014-2999(95)00617-6","volume":"294","author":"GM Gonzalez-Alvear","year":"1995","unstructured":"Gonzalez-Alvear GM, Werling LL (1995) sigma1 receptors in rat striatum regulate NMDA-stimulated [3H]dopamine release via a presynaptic mechanism. Eur J Pharmacol 294:713\u2013719. https:\/\/doi.org\/10.1016\/0014-2999(95)00617-6","journal-title":"Eur J Pharmacol"},{"key":"2306_CR118","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00000539-200107000-00038","volume":"93","author":"A Gottschalk","year":"2001","unstructured":"Gottschalk A, Schroeder F, Ufer M, Oncu A, Buerkle H, Standl T (2001) Amantadine, a N-methyl-d-aspartate receptor antagonist, does not enhance postoperative analgesia in women undergoing abdominal hysterectomy. Anesth Analg 93:192\u2013196","journal-title":"Anesth Analg"},{"key":"2306_CR119","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1176\/appi.ajp.162.9.1744","volume":"162","author":"KA Graham","year":"2005","unstructured":"Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO (2005) Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162:1744\u20131746. https:\/\/doi.org\/10.1176\/appi.ajp.162.9.1744","journal-title":"Am J Psychiatry"},{"key":"2306_CR120","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/WNF.0000000000000242","volume":"40","author":"JA Gramish","year":"2017","unstructured":"Gramish JA, Kopp BJ, Patanwala AE (2017) Effect of amantadine on agitation in critically ill patients with traumatic brain injury. Clin Neuropharmacol 40:212\u2013216. https:\/\/doi.org\/10.1097\/WNF.0000000000000242","journal-title":"Clin Neuropharmacol"},{"key":"2306_CR121","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/01.phm.0000143400.15346.c8","volume":"83","author":"LB Green","year":"2004","unstructured":"Green LB, Hornyak JE, Hurvitz EA (2004) Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study. Am J Phys Med Rehabil 83:893\u2013897. https:\/\/doi.org\/10.1097\/01.phm.0000143400.15346.c8","journal-title":"Am J Phys Med Rehabil"},{"key":"2306_CR122","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/j.1552-4604.1977.tb01545.x","volume":"17","author":"DJ Greenblatt","year":"1977","unstructured":"Greenblatt DJ, DiMascio A, Harmatz JS, Bernardo DL, Marder JE (1977) Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms. J Clin Pharmacol 17:704\u2013708. https:\/\/doi.org\/10.1002\/j.1552-4604.1977.tb01545.x","journal-title":"J Clin Pharmacol"},{"key":"2306_CR123","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1126\/science.169.3941.203","volume":"169","author":"RP Grelak","year":"1970","unstructured":"Grelak RP, Clark R, Stump JM, Vernier VG (1970) Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science 169:203\u2013204. https:\/\/doi.org\/10.1126\/science.169.3941.203","journal-title":"Science"},{"key":"2306_CR124","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00002826-198908000-00003","volume":"12","author":"T Gualtieri","year":"1989","unstructured":"Gualtieri T, Chandler M, Coons TB, Brown LT (1989) Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 12:258\u2013270","journal-title":"Clin Neuropharmacol"},{"key":"2306_CR125","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0014-2999(95)00415-8","volume":"286","author":"GA Gudelsky","year":"1995","unstructured":"Gudelsky GA (1995) Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur J Pharmacol 286:223\u2013228. https:\/\/doi.org\/10.1016\/0014-2999(95)00415-8","journal-title":"Eur J Pharmacol"},{"key":"2306_CR126","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1017\/s0317167100026603","volume":"14","author":"W Hader","year":"1987","unstructured":"Hader W et al (1987) A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group. Can J Neurol Sci 14:273\u2013278. https:\/\/doi.org\/10.1017\/s0317167100026603","journal-title":"Can J Neurol Sci"},{"key":"2306_CR127","first-page":"2043","volume":"142","author":"V Hallensleben","year":"1997","unstructured":"Hallensleben V, Zocher M, Staeheli P (1997) Borna disease virus is not sensitive to amantadine. ArchVirol 142:2043\u20132048","journal-title":"ArchVirol"},{"key":"2306_CR128","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/01.HTR.0000438116.56228.de","volume":"29","author":"FM Hammond","year":"2014","unstructured":"Hammond FM, Bickett AK, Norton JH, Pershad R (2014) Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression. J Head Trauma Rehabil 29:391\u2013399. https:\/\/doi.org\/10.1097\/01.HTR.0000438116.56228.de","journal-title":"J Head Trauma Rehabil"},{"key":"2306_CR129","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1089\/neu.2014.3803","volume":"32","author":"FM Hammond","year":"2015","unstructured":"Hammond FM et al (2015) Amantadine effect on perceptions of irritability after traumatic brain injury: results of the amantadine irritability multisite study. J Neurotrauma 32:1230\u20131238. https:\/\/doi.org\/10.1089\/neu.2014.3803","journal-title":"J Neurotrauma"},{"key":"2306_CR130","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1089\/neu.2018.5767","volume":"35","author":"FM Hammond","year":"2018","unstructured":"Hammond FM et al (2018) Amantadine did not positively impact cognition in chronic traumatic brain injury: a multi-site, randomized, controlled trial. J Neurotrauma 35:2298\u20132305. https:\/\/doi.org\/10.1089\/neu.2018.5767","journal-title":"J Neurotrauma"},{"key":"2306_CR131","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40262-018-0663-4","volume":"58","author":"RA Hauser","year":"2019","unstructured":"Hauser RA et al (2019) Pharmacokinetics of ADS-5102 (Amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet 58:77\u201388. https:\/\/doi.org\/10.1007\/s40262-018-0663-4","journal-title":"Clin Pharmacokinet"},{"key":"2306_CR132","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1128\/aac.23.3.458","volume":"23","author":"FG Hayden","year":"1983","unstructured":"Hayden FG, Hoffman HE, Spyker DA (1983) Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother 23:458\u2013464. https:\/\/doi.org\/10.1128\/aac.23.3.458","journal-title":"Antimicrob Agents Chemother"},{"key":"2306_CR133","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0014-2999(72)90144-6","volume":"20","author":"RE Heikkila","year":"1972","unstructured":"Heikkila RE, Cohen G (1972) Evaluation of amantadine as a releasing agent or uptake blocker for H3-dopamine in rat brain slices. Eur J Pharmacol 20:156\u2013160","journal-title":"Eur J Pharmacol"},{"key":"2306_CR134","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/0006-2952(72)90013-5","volume":"21","author":"WF Herblin","year":"1972","unstructured":"Herblin WF (1972) Amantadine and catecholamine uptake. Biochem Pharmacol 21:1993\u20131995. https:\/\/doi.org\/10.1016\/0006-2952(72)90013-5","journal-title":"Biochem Pharmacol"},{"key":"2306_CR135","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1023\/A:1018856020583","volume":"16","author":"MB Hesselink","year":"1999","unstructured":"Hesselink MB, DeBoer BG, Breimer DD, Danysz W (1999) Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study. Pharm Res 16:637\u2013642","journal-title":"Pharm Res"},{"key":"2306_CR136","doi-asserted-by":"publisher","first-page":"e86354","DOI":"10.1371\/journal.pone.0086354","volume":"9","author":"EY Huang","year":"2014","unstructured":"Huang EY et al (2014) Amantadine ameliorates dopamine-releasing deficits and behavioral deficits in rats after fluid percussion injury. PLoS ONE 9:e86354. https:\/\/doi.org\/10.1371\/journal.pone.0086354","journal-title":"PLoS ONE"},{"key":"2306_CR137","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","volume":"78","author":"G Hubsher","year":"2012","unstructured":"Hubsher G, Haider M, Okun MS (2012) Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 78:1096\u20131099. https:\/\/doi.org\/10.1212\/WNL.0b013e31824e8f0d","journal-title":"Neurology"},{"key":"2306_CR138","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/02699050500309296","volume":"19","author":"S Hughes","year":"2005","unstructured":"Hughes S, Colantonio A, Santaguida PL, Paton T (2005) Amantadine to enhance readiness for rehabilitation following severe traumatic brain injury. Brain Inj BI 19:1197\u20131206. https:\/\/doi.org\/10.1080\/02699050500309296","journal-title":"Brain Inj BI"},{"key":"2306_CR139","first-page":"21","volume":"320","author":"R Jackisch","year":"1992","unstructured":"Jackisch R, Link T, Neufang B, Koch R (1992) Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine - no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 320:21\u201342","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2306_CR140","first-page":"93","volume":"29","author":"W Janiec","year":"1977","unstructured":"Janiec W, Piekarska T, Szczypior M, Misterkiewicz E (1977) The effect of apomorphine, amantadine and dimethylaminoadamantane on the level of cyclic AMP in the rat striatum. Pol J Pharmacol Pharm 29:93\u201399","journal-title":"Pol J Pharmacol Pharm"},{"key":"2306_CR141","first-page":"529","volume":"30","author":"W Janiec","year":"1978","unstructured":"Janiec W, Piekarska T, Paletko Z, Pytlik M (1978) The effect of drugs stimulating central dopaminergic system on transformation of exogenous adenine into c-AMP. Pol J Pharmacol Pharm 30:529\u2013535","journal-title":"Pol J Pharmacol Pharm"},{"key":"2306_CR142","first-page":"1","volume":"24","author":"WJ Ji","year":"2014","unstructured":"Ji WJ, Jiang X, Chen HY (2014) A randomized, double-blind and controlled study of olanzapine plus amantadine in patients with first episode schizophrenia. J Clin Psychiatry 24:1\u20133","journal-title":"J Clin Psychiatry"},{"key":"2306_CR143","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.3892\/mmr.2017.7185","volume":"16","author":"LL Ji","year":"2017","unstructured":"Ji LL, Peng JB, Fu CH, Tong L, Wang ZY (2017) Sigma-1 receptor activation ameliorates anxiety-like behavior through NR2A-CREB-BDNF signaling pathway in a rat model submitted to single-prolonged stress. Mol Med Rep 16:4987\u20134993. https:\/\/doi.org\/10.3892\/mmr.2017.7185","journal-title":"Mol Med Rep"},{"key":"2306_CR144","doi-asserted-by":"publisher","first-page":"e1004320","DOI":"10.1371\/journal.ppat.1004320","volume":"10","author":"JM Jimenez-Guardeno","year":"2014","unstructured":"Jimenez-Guardeno JM, Nieto-Torres JL, DeDiego ML, Regla-Nava JA, Fernandez-Delgado R, Castano-Rodriguez C, Enjuanes L (2014) The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis. PLoS Pathog 10:e1004320. https:\/\/doi.org\/10.1371\/journal.ppat.1004320","journal-title":"PLoS Pathog"},{"key":"2306_CR145","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0022-510x(72)90030-5","volume":"17","author":"DG Jones","year":"1972","unstructured":"Jones DG, Turnbull MJ, Lenman JA, Robertson MA (1972) Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects. J Neurol Sci 17:245\u2013253. https:\/\/doi.org\/10.1016\/0022-510x(72)90030-5","journal-title":"J Neurol Sci"},{"key":"2306_CR146","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0006-8993(96)01318-2","volume":"749","author":"R Kakkar","year":"1997","unstructured":"Kakkar R, Raju RVS, Rajput AH, Sharma RK (1997) Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain Res 749:290\u2013294","journal-title":"Brain Res"},{"key":"2306_CR147","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/0014-2999(74)90292-1","volume":"28","author":"ME Karobath","year":"1974","unstructured":"Karobath ME (1974) Amantadine and D-145, an amantadine derivative, do not effect dopamine sensitive adenylate cyclase from the caudate-putamen of the rat brain. Eur J Pharmacol 28:376\u2013378","journal-title":"Eur J Pharmacol"},{"key":"2306_CR148","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/00926239708403922","volume":"23","author":"A Keller Ashton","year":"1997","unstructured":"Keller Ashton A, Hamer R, Rosen RC (1997) Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients. J Sex Marital Ther 23:165\u2013175","journal-title":"J Sex Marital Ther"},{"key":"2306_CR149","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/bf01310675","volume":"119","author":"AP Kendal","year":"1991","unstructured":"Kendal AP, Klenk HD (1991) Amantadine inhibits an early, M2 protein-dependent event in the replication cycle of avian influenza (H7) viruses. Arch Virol 119:265\u2013273. https:\/\/doi.org\/10.1007\/bf01310675","journal-title":"Arch Virol"},{"key":"2306_CR150","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3851\/IMP2485","volume":"23","author":"AJ Kesel","year":"2012","unstructured":"Kesel AJ, Weiss HC, Schonleber A, Day CW, Barnard DL, Detorio MA, Schinazi RF (2012) Antiviral agents derived from novel 1-adamantyl singlet nitrenes. Antivir Chem Chemother 23:113\u2013128. https:\/\/doi.org\/10.3851\/IMP2485","journal-title":"Antivir Chem Chemother"},{"key":"2306_CR151","first-page":"37","volume":"109","author":"DR Khasanova","year":"2009","unstructured":"Khasanova DR, Saikhunov MV, Kitaeva EA, Khafiz\u2019ianova R, Islaamov RR, Demin TV (2009) [Amantadine sulfate (PK-Merz) in the treatment of ischemic stroke: a clinical-experimental study] Zhurnal nevrologii i psikhiatrii imeni SS Korsakova \/ Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii. Vserossiiskoe obshchestvo psikhiat [i] Vserossiiskoe obshchestvo psikhiat 109:37\u201343","journal-title":"Vserossiiskoe obshchestvo psikhiat [i] Vserossiiskoe obshchestvo psikhiat"},{"key":"2306_CR152","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40169-019-0239-4","volume":"8","author":"M Khazaei","year":"2019","unstructured":"Khazaei M, Karevan A, Taheri M, Ghafouri-Fard S (2019) Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis. Clin Transl Med 8:20. https:\/\/doi.org\/10.1186\/s40169-019-0239-4","journal-title":"Clin Transl Med"},{"key":"2306_CR153","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/j.neurobiolaging.2011.08.011","volume":"33","author":"JH Kim","year":"2012","unstructured":"Kim JH et al (2012) Microglia-inhibiting activity of Parkinson\u2019s disease drug amantadine. Neurobiol Aging 33:2145\u20132159. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.08.011","journal-title":"Neurobiol Aging"},{"key":"2306_CR154","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.jpsychires.2013.04.013","volume":"47","author":"T Kishi","year":"2013","unstructured":"Kishi T, Iwata N (2013) NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res 47:1143\u20131149. https:\/\/doi.org\/10.1016\/j.jpsychires.2013.04.013","journal-title":"J Psychiatr Res"},{"key":"2306_CR155","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0014-2999(89)90384-1","volume":"166","author":"J Kornhuber","year":"1989","unstructured":"Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P (1989) Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166:589\u2013590","journal-title":"Eur J Pharmacol"},{"key":"2306_CR156","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","volume":"206","author":"J Kornhuber","year":"1991","unstructured":"Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel\u2014a human postmortem brain study. Eur J Pharmacol 206:297\u2013300","journal-title":"Eur J Pharmacol"},{"key":"2306_CR157","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0304-3940(93)90362-O","volume":"163","author":"J Kornhuber","year":"1993","unstructured":"Kornhuber J, Schoppmeyer K, Riederer P (1993) Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci Lett 163:129\u2013131","journal-title":"Neurosci Lett"},{"key":"2306_CR158","first-page":"91","volume":"43","author":"J Kornhuber","year":"1994","unstructured":"Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43:91\u2013104","journal-title":"J Neural Transm Suppl"},{"key":"2306_CR159","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/0028-3908(95)00056-C","volume":"34","author":"J Kornhuber","year":"1995","unstructured":"Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P (1995) Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34:713\u2013721","journal-title":"Neuropharmacology"},{"key":"2306_CR160","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.13005\/bpj\/1746","volume":"12","author":"K Kranthi","year":"2019","unstructured":"Kranthi K, Anand Priya VVM, Punnagai K, Chellathai David D (2019) A comparative free radical scavenging evaluation of amantadine and rasagiline. Biomed Pharmacol J 12:1175\u20131179. https:\/\/doi.org\/10.13005\/bpj\/1746","journal-title":"Biomed Pharmacol J"},{"key":"2306_CR161","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1176\/jnp.9.2.222","volume":"9","author":"MF Kraus","year":"1997","unstructured":"Kraus MF, Maki PM (1997) Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci 9:222\u2013230. https:\/\/doi.org\/10.1176\/jnp.9.2.222","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2306_CR162","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/026990597123430","volume":"11","author":"MF Kraus","year":"1997","unstructured":"Kraus MF, Maki P (1997) The combined use of amantadine and l-dopa\/carbidopa in the treatment of chronic brain injury. Brain Inj 11:455\u2013460","journal-title":"Brain Inj"},{"key":"2306_CR163","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/02699050400025059","volume":"19","author":"MF Kraus","year":"2005","unstructured":"Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, Marion D (2005) Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Inj BI 19:471\u2013479. https:\/\/doi.org\/10.1080\/02699050400025059","journal-title":"Brain Inj BI"},{"key":"2306_CR164","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11055-010-9292-6","volume":"40","author":"OV Krivonos","year":"2010","unstructured":"Krivonos OV, Amosova NA, Smolentseva IG (2010) Use of the glutamate NMDA receptor antagonist PK-Merz in acute stroke. Neurosci Behav Physiol 40:529\u2013532","journal-title":"Neurosci Behav Physiol"},{"key":"2306_CR165","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/MEG.0b013e3281ac20ca","volume":"19","author":"B Kronenberger","year":"2007","unstructured":"Kronenberger B et al (2007) Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. Eur J Gastroenterol Hepatol 19:639\u2013646. https:\/\/doi.org\/10.1097\/MEG.0b013e3281ac20ca","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2306_CR166","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1212\/WNL.45.11.1956","volume":"45","author":"LB Krupp","year":"1995","unstructured":"Krupp LB et al (1995) Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 45:1956\u20131961","journal-title":"Neurology"},{"key":"2306_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/ph13100326","author":"M Krzystanek","year":"2020","unstructured":"Krzystanek M, Palasz A (2020) Possibility of a new indication for amantadine in the treatment of bipolar depression-case series study. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph13100326","journal-title":"Pharmaceuticals (Basel)"},{"key":"2306_CR168","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S1734-1140(09)70173-2","volume":"61","author":"M Kubera","year":"2009","unstructured":"Kubera M et al (2009) Inhibitory effects of amantadine on the production of pro-inflammatory cytokines by stimulated in vitro human blood. Pharmacol Rep PR 61:1105\u20131112","journal-title":"Pharmacol Rep PR"},{"key":"2306_CR169","first-page":"367","volume":"5","author":"R Lalonde","year":"1993","unstructured":"Lalonde R, Joyal CC, Guastavino JM, Cote C, Botez MI (1993) Amantadine and ketamine-induced improvement of motor coordination in lurcher mutant mice. Restor Neurol Neurosci 5:367\u2013370","journal-title":"Restor Neurol Neurosci"},{"key":"2306_CR170","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/00001756-199107000-00004","volume":"2","author":"H Lampe","year":"1991","unstructured":"Lampe H, Bigalke H (1991) Modulation of glycine activated membrane current by adamantane derivatives. NeuroReport 2:373\u2013376","journal-title":"NeuroReport"},{"key":"2306_CR171","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3892\/ijmm.2015.2289","volume":"36","author":"Z Lan","year":"2015","unstructured":"Lan Z, Chong Z, Liu C, Feng D, Fang D, Zang W, Zhou J (2015) Amantadine inhibits cellular proliferation and induces the apoptosis of hepatocellular cancer cells in vitro. Int J Mol Med 36:904\u2013910. https:\/\/doi.org\/10.3892\/ijmm.2015.2289","journal-title":"Int J Mol Med"},{"key":"2306_CR172","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1515\/revneuro.1996.7.3.165","volume":"7","author":"PA Lapchak","year":"1996","unstructured":"Lapchak PA (1996) Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities. CNS Rev Neurosci 7:165\u2013176. https:\/\/doi.org\/10.1515\/revneuro.1996.7.3.165","journal-title":"CNS Rev Neurosci"},{"key":"2306_CR173","unstructured":"Larue D, Guillot C, Guerrier M, Kato G (1987) Receptor binding studies with memantine"},{"key":"2306_CR174","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.tics.2005.10.010","volume":"9","author":"S Laureys","year":"2005","unstructured":"Laureys S (2005) The neural correlate of (un)awareness: lessons from the vegetative state. Trends Cogn Sci 9:556\u2013559. https:\/\/doi.org\/10.1016\/j.tics.2005.10.010","journal-title":"Trends Cogn Sci"},{"key":"2306_CR175","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1006\/nimg.1998.0414","volume":"9","author":"S Laureys","year":"1999","unstructured":"Laureys S et al (1999) Impaired effective cortical connectivity in vegetative state: preliminary investigation using PET. Neuroimage 9:377\u2013382. https:\/\/doi.org\/10.1006\/nimg.1998.0414","journal-title":"Neuroimage"},{"key":"2306_CR176","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/s0140-6736(00)02271-6","volume":"355","author":"S Laureys","year":"2000","unstructured":"Laureys S, Faymonville ME, Luxen A, Lamy M, Franck G, Maquet P (2000) Restoration of thalamocortical connectivity after recovery from persistent vegetative state. Lancet 355:1790\u20131791. https:\/\/doi.org\/10.1016\/s0140-6736(00)02271-6","journal-title":"Lancet"},{"key":"2306_CR177","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-020-00986-4","author":"AM Leclerc","year":"2020","unstructured":"Leclerc AM et al (2020) Amantadine and modafinil as neurostimulants following acute stroke: a retrospective study of intensive care unit patients. Neurocrit Care. https:\/\/doi.org\/10.1007\/s12028-020-00986-4","journal-title":"Neurocrit Care"},{"issue":"Suppl 1","key":"2306_CR178","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.clineuro.2013.09.029","volume":"115","author":"AH Ledinek","year":"2013","unstructured":"Ledinek AH, Sajko MC, Rot U (2013) Evaluating the effects of amantadin, modafinil and acetyl-l-carnitine on fatigue in multiple sclerosis-result of a pilot randomized, blind study. Clin Neurol Neurosurg 115(Suppl 1):S86-89. https:\/\/doi.org\/10.1016\/j.clineuro.2013.09.029","journal-title":"Clin Neurol Neurosurg"},{"key":"2306_CR179","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/(SICI)1097-4547(19980815)53:4<490::AID-JNR11>3.0.CO;2-6","volume":"53","author":"XM Li","year":"1998","unstructured":"Li XM, Juorio AV, Qi J, Boulton AA (1998) Amantadine increases aromatic l-amino acid decarboxylase mRNA in PC12 cells. J Neurosci Res 53:490\u2013493","journal-title":"J Neurosci Res"},{"key":"2306_CR180","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1021\/cn300180a","volume":"4","author":"W Limapichat","year":"2013","unstructured":"Limapichat W, Yu WY, Branigan E, Lester HA, Dougherty DA (2013) Key binding interactions for memantine in the NMDA receptor. ACS Chem Neurosci 4:255\u2013260. https:\/\/doi.org\/10.1021\/cn300180a","journal-title":"ACS Chem Neurosci"},{"key":"2306_CR181","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/smrv.2000.0116","volume":"4","author":"JS Lin","year":"2000","unstructured":"Lin JS (2000) Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 4:471\u2013503. https:\/\/doi.org\/10.1053\/smrv.2000.0116","journal-title":"Sleep Med Rev"},{"key":"2306_CR182","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1212\/01.WNL.0000068165.07883.64","volume":"60","author":"C Lucetti","year":"2003","unstructured":"Lucetti C et al (2003) IV amantadine improves chorea in Huntington\u2019s disease: an acute randomized, controlled study. Neurology 60:1995\u20131997","journal-title":"Neurology"},{"key":"2306_CR183","first-page":"717","volume":"263","author":"A Lupp","year":"1992","unstructured":"Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-d-aspartate-evoked acetylcholine release in the rabbit caudate nucleus. In Vitro J Pharmacol Exp Ther 263:717\u2013724","journal-title":"In Vitro J Pharmacol Exp Ther"},{"key":"2306_CR184","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0006-8993(92)91517-I","volume":"597","author":"HS Lustig","year":"1992","unstructured":"Lustig HS, Ahern KV, Greenberg DA (1992) Antiparkinsonian drugs and invitro excitotoxicity. Brain Res 597:148\u2013150","journal-title":"Brain Res"},{"key":"2306_CR185","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/02699052.2020.1723697","volume":"34","author":"HM Ma","year":"2020","unstructured":"Ma HM, Zafonte RD (2020) Amantadine and memantine: a comprehensive review for acquired brain injury. Brain Inj 34:299\u2013315","journal-title":"Brain Inj"},{"key":"2306_CR186","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0014-2999(74)90067-3","volume":"26","author":"J Maj","year":"1974","unstructured":"Maj J, Sowinska H, Baran L, Sarnek J (1974) Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative. Eur J Pharmacol 26:9\u201314","journal-title":"Eur J Pharmacol"},{"key":"2306_CR187","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s13311-012-0140-y","volume":"9","author":"R Mancuso","year":"2012","unstructured":"Mancuso R, Olivan S, Rando A, Casas C, Osta R, Navarro X (2012) Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics 9:814\u2013826. https:\/\/doi.org\/10.1007\/s13311-012-0140-y","journal-title":"Neurotherapeutics"},{"key":"2306_CR188","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/ana.410090219","volume":"9","author":"BV Manyam","year":"1981","unstructured":"Manyam BV (1981) Amantadine in essential tremor. Ann Neurol 9:198\u2013199. https:\/\/doi.org\/10.1002\/ana.410090219","journal-title":"Ann Neurol"},{"key":"2306_CR189","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/depr.3050020608","volume":"2","author":"PS Masand","year":"1994","unstructured":"Masand PS, Reddy N, Gregory R (1994) SSRI-induced sexual dysfunction successfully treated with amantadine. Depression 2:319\u2013321. https:\/\/doi.org\/10.1002\/depr.3050020608","journal-title":"Depression"},{"key":"2306_CR190","first-page":"834","volume":"281","author":"H Matsubayashi","year":"1997","unstructured":"Matsubayashi H, Swanson KL, Albuquerque EX (1997) Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. J Pharmacol Exp Ther 281:834\u2013844","journal-title":"J Pharmacol Exp Ther"},{"key":"2306_CR191","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1126\/science.386515","volume":"206","author":"TH Maugh 2nd","year":"1979","unstructured":"Maugh TH 2nd (1979) Panel urges wide use of antiviral drug. Science 206:1058\u20131060. https:\/\/doi.org\/10.1126\/science.386515","journal-title":"Science"},{"key":"2306_CR192","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0278-5846(96)00160-1","volume":"21","author":"T Maurice","year":"1997","unstructured":"Maurice T, Lockhart BP (1997) Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands Progress. Neuropsychopharmacol Biol Psychiatry 21:69\u2013102","journal-title":"Neuropsychopharmacol Biol Psychiatry"},{"key":"2306_CR193","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/PHM.0b013e3181a5ade3","volume":"88","author":"MA McMahon","year":"2009","unstructured":"McMahon MA, Vargus-Adams JN, Michaud LJ, Bean J (2009) Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study. Am J Phys Med Rehabil 88:525\u2013532. https:\/\/doi.org\/10.1097\/PHM.0b013e3181a5ade3","journal-title":"Am J Phys Med Rehabil"},{"key":"2306_CR194","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0197-0186(87)90007-6","volume":"11","author":"S Medrano","year":"1987","unstructured":"Medrano S, Ochoa EL, McNamee MG (1987) The effect of amantadine on nicotinic acetylcholine receptor (nAchR) in reconstituted membranes. Neurochem Int 11:175\u2013181. https:\/\/doi.org\/10.1016\/0197-0186(87)90007-6","journal-title":"Neurochem Int"},{"key":"2306_CR195","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/s1098-7339(99)90045-7","volume":"24","author":"T Medrik-Goldberg","year":"1999","unstructured":"Medrik-Goldberg T, Lifschitz D, Pud D, Adler R, Eisenberg E (1999) Intravenous lidocaine, amantadine, and placebo in the treatment of sciatica: a double-blind, randomized, controlled study. Reg Anesth Pain Med 24:534\u2013540. https:\/\/doi.org\/10.1016\/s1098-7339(99)90045-7","journal-title":"Reg Anesth Pain Med"},{"key":"2306_CR196","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0149-7634(88)80046-0","volume":"12","author":"FS Messiha","year":"1988","unstructured":"Messiha FS (1988) Effect of amantadine on chlorpromazine and reserpine induced behavioral depression in the mouse. Neurosci Biobehav Rev 12:219\u2013222","journal-title":"Neurosci Biobehav Rev"},{"key":"2306_CR197","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/sj.bjp.0706927","volume":"149","author":"J Meunier","year":"2006","unstructured":"Meunier J, Ieni J, Maurice T (2006) The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25\u201335 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 149:998\u20131012","journal-title":"Br J Pharmacol"},{"key":"2306_CR198","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/00001199-200208000-00004","volume":"17","author":"JM Meythaler","year":"2002","unstructured":"Meythaler JM, Brunner RC, Johnson A, Novack TA (2002) Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil 17:300\u2013313","journal-title":"J Head Trauma Rehabil"},{"key":"2306_CR199","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/RNN-2010-0528","volume":"28","author":"JE Minnich","year":"2010","unstructured":"Minnich JE et al (2010) Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects cortical neurons from dying following a traumatic brain injury. Restor Neurol Neurosci 28:293\u2013309. https:\/\/doi.org\/10.3233\/RNN-2010-0528","journal-title":"Restor Neurol Neurosci"},{"key":"2306_CR200","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1042\/BC20040149","volume":"97","author":"FP Monnet","year":"2005","unstructured":"Monnet FP (2005) Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance. Biol Cell Under Auspices Eur Cell Biol Organ 97:873\u2013883. https:\/\/doi.org\/10.1042\/BC20040149","journal-title":"Biol Cell Under Auspices Eur Cell Biol Organ"},{"key":"2306_CR201","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00702-002-0694-7","volume":"109","author":"RM Moresco","year":"2002","unstructured":"Moresco RM et al (2002) New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET - [(11)C]raclopride study. J Neural Transm 109:1265\u20131274. https:\/\/doi.org\/10.1007\/s00702-002-0694-7","journal-title":"J Neural Transm"},{"key":"2306_CR202","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1124\/jpet.111.190868","volume":"341","author":"T Mori","year":"2012","unstructured":"Mori T, Hayashi T, Su TP (2012) Compromising sigma-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-kappaB\/Bcl-2-dependent mechanism: potential relevance to Parkinson\u2019s disease. J Pharmacol Exp Ther 341:663\u2013671. https:\/\/doi.org\/10.1124\/jpet.111.190868","journal-title":"J Pharmacol Exp Ther"},{"key":"2306_CR203","doi-asserted-by":"publisher","first-page":"e1305","DOI":"10.1371\/journal.pone.0001305","volume":"2","author":"D Morrison","year":"2007","unstructured":"Morrison D, Roy S, Rayner C, Amer A, Howard D, Smith JR, Evans TG (2007) A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS ONE 2:e1305. https:\/\/doi.org\/10.1371\/journal.pone.0001305","journal-title":"PLoS ONE"},{"key":"2306_CR204","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1600-0773.1993.tb01351.x","volume":"72","author":"E Moryl","year":"1993","unstructured":"Moryl E, Danysz W, Quack G (1993) Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 72:394\u2013397","journal-title":"Pharmacol Toxicol"},{"key":"2306_CR205","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/s0317167100047107","volume":"12","author":"TJ Murray","year":"1985","unstructured":"Murray TJ (1985) Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 12:251\u2013254. https:\/\/doi.org\/10.1017\/s0317167100047107","journal-title":"Can J Neurol Sci"},{"key":"2306_CR206","doi-asserted-by":"publisher","DOI":"10.3390\/biom9050191","author":"T Nakano","year":"2019","unstructured":"Nakano T, Hasegawa T, Suzuki D, Motomura E, Okada M (2019) Amantadine combines astroglial system Xc(-) activation with glutamate\/NMDA. Recept Inhib Biomol. https:\/\/doi.org\/10.3390\/biom9050191","journal-title":"Recept Inhib Biomol"},{"key":"2306_CR207","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0014-2999(96)00395-0","volume":"311","author":"VH Nguyen","year":"1996","unstructured":"Nguyen VH, Kassiou M, Johnston GAR, Christie MJ (1996) Comparison of binding parameters of sigma-1 and sigma-2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes. Eur J Pharmacol 311:233\u2013240","journal-title":"Eur J Pharmacol"},{"key":"2306_CR208","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3109\/02699059409151025","volume":"8","author":"JL Nickels","year":"1994","unstructured":"Nickels JL, Schneider WN, Dombovy ML, Wong TM (1994) Clinical use of amantadine in brain injury rehabilitation. Brain Inj 8:709\u2013718","journal-title":"Brain Inj"},{"key":"2306_CR209","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.parkreldis.2008.08.005","volume":"15","author":"N Nishikawa","year":"2009","unstructured":"Nishikawa N, Nagai M, Moritoyo T, Yabe H, Nomoto M (2009) Plasma amantadine concentrations in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 15:351\u2013353. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.08.005","journal-title":"Parkinsonism Relat Disord"},{"key":"2306_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30354-9","author":"B Nourbakhsh","year":"2020","unstructured":"Nourbakhsh B et al (2020) Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(20)30354-9","journal-title":"Lancet Neurol"},{"key":"2306_CR211","doi-asserted-by":"publisher","first-page":"103449","DOI":"10.1016\/j.mcn.2019.103449","volume":"102","author":"JJ O'Brien","year":"2020","unstructured":"O\u2019Brien JJ et al (2020) Inhibition of calcium-calmodulin-dependent phosphodiesterase (PDE1) suppresses inflammatory responses. Mol Cell Neurosci 102:103449. https:\/\/doi.org\/10.1016\/j.mcn.2019.103449","journal-title":"Mol Cell Neurosci"},{"key":"2306_CR212","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0197-0186(83)90037-2","volume":"5","author":"EL Ochoa","year":"1983","unstructured":"Ochoa EL (1983) The effects of amantadine on liposomally reconstituted nicotinic acetylcholine receptor. Neurochem Int 5:339\u2013343. https:\/\/doi.org\/10.1016\/0197-0186(83)90037-2","journal-title":"Neurochem Int"},{"key":"2306_CR213","first-page":"265","volume":"45","author":"J Offermeier","year":"1971","unstructured":"Offermeier J, Dreyer AC (1971) A comparison of the effects of noradrenaline, adrenaline and some phenylephrine derivatives on alpha-, beta- and beta- adrenergic receptors. S Afr Med J 45:265\u2013267","journal-title":"S Afr Med J"},{"key":"2306_CR214","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neulet.2018.11.030","volume":"694","author":"AA Okigbo","year":"2019","unstructured":"Okigbo AA et al (2019) Dose-dependent neurorestorative effects of amantadine after cortical impact injury. Neurosci Lett 694:69\u201373. https:\/\/doi.org\/10.1016\/j.neulet.2018.11.030","journal-title":"Neurosci Lett"},{"key":"2306_CR215","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0014-2999(95)00356-P","volume":"283","author":"M Oneill","year":"1995","unstructured":"Oneill M et al (1995) The sigma receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia. Eur J Pharmacol 283:217\u2013225","journal-title":"Eur J Pharmacol"},{"key":"2306_CR216","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.neuropharm.2011.04.030","volume":"61","author":"B Ossola","year":"2011","unstructured":"Ossola B, Schendzielorz N, Chen SH, Bird GS, Tuominen RK, Mannisto PT, Hong JS (2011) Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology 61:574\u2013582. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.04.030","journal-title":"Neuropharmacology"},{"key":"2306_CR217","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archneur.60.7.996","volume":"60","author":"P O'Suilleabhain","year":"2003","unstructured":"O\u2019Suilleabhain P, Dewey RB Jr (2003) A randomized trial of amantadine in Huntington disease. Arch Neurol 60:996\u2013998. https:\/\/doi.org\/10.1001\/archneur.60.7.996","journal-title":"Arch Neurol"},{"key":"2306_CR218","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.neuropharm.2010.10.008","volume":"60","author":"HJ Otton","year":"2011","unstructured":"Otton HJ, Lawson MA, Pannozzo MA, Davies CH, Wyllie DJ (2011) Quantification of the Mg(2+)-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1\/GluN2A NMDARs. Neuropharmacology 60:388\u2013396. https:\/\/doi.org\/10.1016\/j.neuropharm.2010.10.008","journal-title":"Neuropharmacology"},{"key":"2306_CR219","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1365-2125.1976.tb00642.x","volume":"3","author":"GM Pacifici","year":"1976","unstructured":"Pacifici GM, Nardini M, Ferrari P, Latini R, Fieschi C, Morselli PL (1976) Effect of amantadine on drug-induced parkinsonism: relationship between levels and effect. Br J Clin Pharmacol 3:883\u2013889","journal-title":"Br J Clin Pharmacol"},{"key":"2306_CR220","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","volume":"33","author":"S Pappa","year":"2010","unstructured":"Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S (2010) Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 33:271\u2013275","journal-title":"Clin Neuropharmacol"},{"key":"2306_CR221","first-page":"11","volume":"8","author":"D Parkes","year":"1974","unstructured":"Parkes D (1974) Amantadine advances. Drug Res 8:11\u201381","journal-title":"Drug Res"},{"key":"2306_CR222","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/0028-3908(95)00092-K","volume":"34","author":"CG Parsons","year":"1995","unstructured":"Parsons CG et al (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239\u20131258","journal-title":"Neuropharmacology"},{"key":"2306_CR223","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1460-9568.1996.tb01228.x","volume":"8","author":"CG Parsons","year":"1996","unstructured":"Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA (1996) Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 8:446\u2013454","journal-title":"Eur J Neurosci"},{"key":"2306_CR224","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1177\/08830738060210100901","volume":"21","author":"PD Patrick","year":"2006","unstructured":"Patrick PD, Blackman JA, Mabry JL, Buck ML, Gurka MJ, Conaway MR (2006) Dopamine agonist therapy in low-response children following traumatic brain injury. J Child Neurol 21:879\u2013885. https:\/\/doi.org\/10.1177\/08830738060210100901","journal-title":"J Child Neurol"},{"key":"2306_CR225","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0304-3940(03)00398-7","volume":"343","author":"M Peeters","year":"2003","unstructured":"Peeters M, Maloteaux JM, Hermans E (2003) Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci Lett 343:205\u2013209","journal-title":"Neurosci Lett"},{"key":"2306_CR226","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1111\/j.0953-816X.2004.03297.x","volume":"19","author":"M Peeters","year":"2004","unstructured":"Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E (2004) Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 19:2212\u20132220. https:\/\/doi.org\/10.1111\/j.0953-816X.2004.03297.x","journal-title":"Eur J Neurosci"},{"key":"2306_CR227","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2217\/nmt-2020-0030","volume":"10","author":"DQ Perez","year":"2020","unstructured":"Perez DQ, Espiritu AI, Jamora RDG (2020) Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis. Neurodegener Dis Manag 10:383\u2013395. https:\/\/doi.org\/10.2217\/nmt-2020-0030","journal-title":"Neurodegener Dis Manag"},{"key":"2306_CR228","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2012.02.004","volume":"46","author":"MS Perry","year":"2012","unstructured":"Perry MS, Bailey LJ, Kotecha AC, Malik SI, Hernandez AW (2012) Amantadine for the treatment of refractory absence seizures in children. Pediatr Neurol 46:243\u2013245. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2012.02.004","journal-title":"Pediatr Neurol"},{"key":"2306_CR229","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1212\/wnl.38.9.1478","volume":"38","author":"PL Peterson","year":"1988","unstructured":"Peterson PL, Saad J, Nigro MA (1988) The treatment of Friedreich\u2019s ataxia with amantadine hydrochloride. Neurology 38:1478\u20131480. https:\/\/doi.org\/10.1212\/wnl.38.9.1478","journal-title":"Neurology"},{"key":"2306_CR230","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.rehab.2015.10.003","volume":"59","author":"D Plantier","year":"2016","unstructured":"Plantier D, Luaute J, Group S (2016) Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice. Ann Phys Rehabil Med 59:42\u201357. https:\/\/doi.org\/10.1016\/j.rehab.2015.10.003","journal-title":"Ann Phys Rehabil Med"},{"key":"2306_CR231","first-page":"1","volume":"10","author":"F Plum","year":"1972","unstructured":"Plum F, Posner JB (1972) The diagnosis of stupor and coma. Contemp Neurol Ser 10:1\u2013286","journal-title":"Contemp Neurol Ser"},{"key":"2306_CR232","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1046\/j.1471-4159.1995.64020614.x","volume":"64","author":"RHP Porter","year":"1995","unstructured":"Porter RHP, Greenamyre JT (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64:614\u2013623","journal-title":"J Neurochem"},{"key":"2306_CR233","volume-title":"Diagnosis of stupor and coma","author":"JB Posner","year":"2007","unstructured":"Posner JB, Saper CB, Plum F (2007) Diagnosis of stupor and coma. Oxford University Press, New York"},{"key":"2306_CR234","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/2045125312440441","volume":"2","author":"SK Praharaj","year":"2012","unstructured":"Praharaj SK, Sharma PS (2012) Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol 2:151\u2013156. https:\/\/doi.org\/10.1177\/2045125312440441","journal-title":"Ther Adv Psychopharmacol"},{"key":"2306_CR235","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002818.pub2","author":"E Pucci","year":"2007","unstructured":"Pucci E, Branas P, D\u2019Amico R, Giuliani G, Solari A, Taus C (2007) Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD002818.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2306_CR236","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0304-3959(98)00014-1","volume":"75","author":"D Pud","year":"1998","unstructured":"Pud D, Eisenberg E, Spitzer A, Adler R, Fried G, Yarnitsky D (1998) The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 75:349\u2013354","journal-title":"Pain"},{"key":"2306_CR237","first-page":"97","volume":"46","author":"G Quack","year":"1995","unstructured":"Quack G, Hesselink M, Danysz W, Spanagel R (1995) Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm Suppl 46:97\u2013105","journal-title":"J Neural Transm Suppl"},{"key":"2306_CR238","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/01.WNF.0000220824.57769.E5","volume":"29","author":"LC Quarantini","year":"2006","unstructured":"Quarantini LC et al (2006) Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin Neuropharmacol 29:138\u2013143. https:\/\/doi.org\/10.1097\/01.WNF.0000220824.57769.E5","journal-title":"Clin Neuropharmacol"},{"key":"2306_CR239","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.bcp.2014.03.018","volume":"89","author":"G Quarato","year":"2014","unstructured":"Quarato G, Scrima R, Ripoli M, Agriesti F, Moradpour D, Capitanio N, Piccoli C (2014) Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression. Biochem Pharmacol 89:545\u2013556. https:\/\/doi.org\/10.1016\/j.bcp.2014.03.018","journal-title":"Biochem Pharmacol"},{"key":"2306_CR240","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0167-4943(02)00116-4","volume":"8","author":"R Raffaele","year":"2002","unstructured":"Raffaele R et al (2002) Use of amantadine in the treatment of the neurobehavioral sequelae after brain injury in elderly patients. Arch Gerontol Geriatr Suppl 8:309\u2013312. https:\/\/doi.org\/10.1016\/s0167-4943(02)00116-4","journal-title":"Arch Gerontol Geriatr Suppl"},{"key":"2306_CR241","first-page":"S23","volume":"24","author":"A Rajput","year":"1997","unstructured":"Rajput A, Wallkait M, Rajput AH (1997) 18 month prospective study of amantadine (Amd) for Dopa(LD) induced dyskinesias (DK) in idiopathic Parkinson\u2019s disease. Can J Neurol Sci 24:S23","journal-title":"Can J Neurol Sci"},{"key":"2306_CR242","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0304-3940(01)01872-9","volume":"306","author":"G Rammes","year":"2001","unstructured":"Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG (2001) The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2\/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E\u2013115 cell systems in a non-competitive manner. Neurosci Lett 306:81\u201384","journal-title":"Neurosci Lett"},{"key":"2306_CR243","first-page":"386","volume":"22","author":"MS Rappaport","year":"1996","unstructured":"Rappaport MS, Yells DP (1996) Amantadine induces expression of C-FOS: comparison with apomorphine and MK-801. Soc Neurosci Abs 22:386","journal-title":"Soc Neurosci Abs"},{"key":"2306_CR244","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1590\/1516-4446-2017-2393","volume":"40","author":"IF Raupp-Barcaro","year":"2018","unstructured":"Raupp-Barcaro IF, Vital MA, Galduroz JC, Andreatini R (2018) Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials. Braz J Psychiatry 40:449\u2013458. https:\/\/doi.org\/10.1590\/1516-4446-2017-2393","journal-title":"Braz J Psychiatry"},{"key":"2306_CR245","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/HTR.0b013e318257fbc6","volume":"28","author":"CC Reddy","year":"2013","unstructured":"Reddy CC, Collins M, Lovell M, Kontos AP (2013) Efficacy of amantadine treatment on symptoms and neurocognitive performance among adolescents following sports-related concussion. J Head Trauma Rehabil 28:260\u2013265. https:\/\/doi.org\/10.1097\/HTR.0b013e318257fbc6","journal-title":"J Head Trauma Rehabil"},{"key":"2306_CR246","doi-asserted-by":"publisher","first-page":"102163","DOI":"10.1016\/j.msard.2020.102163","volume":"42","author":"K Rejdak","year":"2020","unstructured":"Rejdak K, Grieb P (2020) Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord 42:102163. https:\/\/doi.org\/10.1016\/j.msard.2020.102163","journal-title":"Mult Scler Relat Disord"},{"key":"2306_CR247","unstructured":"Riederer P (1979) Einflu\u00df von Amantadin und Memantine (D145) auf das Adenylatcyclase-System. Personal communication, February 9, 1979"},{"key":"2306_CR248","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00702-020-02230-x","volume":"127","author":"P Riederer","year":"2020","unstructured":"Riederer P, Ter Meulen V (2020) Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses. J Neural Transm (Vienna) 127:1217\u20131228. https:\/\/doi.org\/10.1007\/s00702-020-02230-x","journal-title":"J Neural Transm (Vienna)"},{"key":"2306_CR249","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF01928264","volume":"28","author":"UK Rinne","year":"1972","unstructured":"Rinne UK, Sonninen V, Hyyppa M (1972) On the effect of amantadine on monoamines and their metabolites in the brain and cerebrospinal fluid. Experientia 28:57\u201359. https:\/\/doi.org\/10.1007\/BF01928264","journal-title":"Experientia"},{"key":"2306_CR250","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/BF00567008","volume":"5","author":"M Rizzo","year":"1973","unstructured":"Rizzo M, Biandrate P, Tognoni G, Morselli PL (1973) Amantadine in depression: relationship between behavioural effects and plasma levels. Eur J Clin Pharmacol 5:226\u2013228","journal-title":"Eur J Clin Pharmacol"},{"key":"2306_CR251","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ana.410080414","volume":"8","author":"WC Robertson Jr","year":"1980","unstructured":"Robertson WC Jr, Clark DB, Markesbery WR (1980) Review of 38 cases of subacute sclerosing panencephalitis: effect of amantadine on the natural course of the disease. Ann Neurol 8:422\u2013425. https:\/\/doi.org\/10.1002\/ana.410080414","journal-title":"Ann Neurol"},{"key":"2306_CR252","first-page":"179","volume":"56","author":"Z Rogoz","year":"2004","unstructured":"Rogoz Z, Skuza G, Kusmider M, Wojcikowski J, Kot M, Daniel WA (2004) Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behav Pharmacokinet Stud Pol J Pharmacol 56:179\u2013185","journal-title":"Behav Pharmacokinet Stud Pol J Pharmacol"},{"key":"2306_CR253","first-page":"219","volume":"58","author":"Z Rogoz","year":"2007","unstructured":"Rogoz Z, Skuza G, Legutko B (2007) Repeated co-treatment with imipramine and amantadine induces hippocampal brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol Off J Pol Physiol Soc 58:219\u2013234","journal-title":"J Physiol Pharmacol Off J Pol Physiol Soc"},{"key":"2306_CR254","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ddr.430290309","volume":"29","author":"P Rojas","year":"1993","unstructured":"Rojas P, Altagracia M, Kravzov J, Rios C (1993) Amantadine increases striatal dopamine turnover in MPTP-treated mice. Drug Dev Res 29:222\u2013226","journal-title":"Drug Dev Res"},{"key":"2306_CR255","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/archneur.1988.00520340058012","volume":"45","author":"GA Rosenberg","year":"1988","unstructured":"Rosenberg GA, Appenzeller O (1988) Amantadine, fatigue, and multiple sclerosis. Arch Neurol 45:1104\u20131106. https:\/\/doi.org\/10.1001\/archneur.1988.00520340058012","journal-title":"Arch Neurol"},{"key":"2306_CR256","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3109\/10799893.2015.1015737","volume":"36","author":"CG Rousseaux","year":"2015","unstructured":"Rousseaux CG, Greene SF (2015) Sigma receptors [sigmaRs]: biology in normal and diseased states. J Recept Signal Transduct Res 36:327\u2013388. https:\/\/doi.org\/10.3109\/10799893.2015.1015737","journal-title":"J Recept Signal Transduct Res"},{"key":"2306_CR257","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fnins.2019.00862","volume":"13","author":"DA Ryskamp","year":"2019","unstructured":"Ryskamp DA, Korban S, Zhemkov V, Kraskovskaya N, Bezprozvanny I (2019) Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases. Front Neurosci 13:862. https:\/\/doi.org\/10.3389\/fnins.2019.00862","journal-title":"Front Neurosci"},{"key":"2306_CR258","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neuint.2014.10.004","volume":"79","author":"G Sancesario","year":"2014","unstructured":"Sancesario G et al (2014) Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism? Neurochem Int 79:44\u201356. https:\/\/doi.org\/10.1016\/j.neuint.2014.10.004","journal-title":"Neurochem Int"},{"key":"2306_CR259","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/jnnp.42.10.960","volume":"42","author":"WL Sanders","year":"1979","unstructured":"Sanders WL (1979) Creutzfeldt-Jakob disease treated with amantadine. J Neurol Neurosurg Psychiatry 42:960\u2013961. https:\/\/doi.org\/10.1136\/jnnp.42.10.960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2306_CR260","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00702-004-0112-4","volume":"111","author":"B Saniova","year":"2004","unstructured":"Saniova B, Drobny M, Kneslova L, Minarik M (2004) The outcome of patients with severe head injuries treated with amantadine sulphate. J Neural Transm (Vienna) 111:511\u2013514. https:\/\/doi.org\/10.1007\/s00702-004-0112-4","journal-title":"J Neural Transm (Vienna)"},{"key":"2306_CR261","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s10571-006-9033-0","volume":"26","author":"B Saniova","year":"2006","unstructured":"Saniova B, Drobny M, Lehotsky J, Sulaj M, Schudichova J (2006) Biochemical and clinical improvement of cytotoxic state by amantadine sulphate. Cell Mol Neurobiol 26:1475\u20131482. https:\/\/doi.org\/10.1007\/s10571-006-9033-0","journal-title":"Cell Mol Neurobiol"},{"key":"2306_CR262","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1345\/aph.1K284","volume":"42","author":"E Sawyer","year":"2008","unstructured":"Sawyer E, Mauro LS, Ohlinger MJ (2008) Amantadine enhancement of arousal and cognition after traumatic brain injury. Ann Pharmacother 42:247\u2013252. https:\/\/doi.org\/10.1345\/aph.1K284","journal-title":"Ann Pharmacother"},{"key":"2306_CR263","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0014-2999(70)90194-9","volume":"13","author":"B Scatton","year":"1970","unstructured":"Scatton B, Cheramy A, Besson MJ, Glowinski J (1970) Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol 13:131\u2013133","journal-title":"Eur J Pharmacol"},{"key":"2306_CR264","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1196\/annals.1417.029","volume":"1129","author":"ND Schiff","year":"2008","unstructured":"Schiff ND (2008) Central thalamic contributions to arousal regulation and neurological disorders of consciousness. Ann N Y Acad Sci 1129:105\u2013118. https:\/\/doi.org\/10.1196\/annals.1417.029","journal-title":"Ann N Y Acad Sci"},{"key":"2306_CR265","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/jnnp.2007.124099","volume":"79","author":"C Schnakers","year":"2008","unstructured":"Schnakers C et al (2008) Measuring the effect of amantadine in chronic anoxic minimally conscious state. J Neurol Neurosurg Psychiatry 79:225\u2013227. https:\/\/doi.org\/10.1136\/jnnp.2007.124099","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2306_CR266","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/026990599121061","volume":"13","author":"WN Schneider","year":"1999","unstructured":"Schneider WN, Drew-Cates J, Wong TM, Dombovy ML (1999) Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study. Brain Inj 13:863\u2013872","journal-title":"Brain Inj"},{"key":"2306_CR267","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1001\/jama.1969.03160070046011","volume":"208","author":"RS Schwab","year":"1969","unstructured":"Schwab RS, England AC Jr, Poskanzer DC, Young RR (1969) Amantadine in the treatment of Parkinson\u2019s disease. JAMA 208:1168\u20131170","journal-title":"JAMA"},{"key":"2306_CR268","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1001\/jama.222.7.792","volume":"222","author":"RS Schwab","year":"1972","unstructured":"Schwab RS, Poskanzer DC, England AC Jr, Young RR (1972) Amantadine in Parkinson\u2019s disease. Review of more than two years\u2019 experience. JAMA 222:792\u2013795. https:\/\/doi.org\/10.1001\/jama.222.7.792","journal-title":"JAMA"},{"key":"2306_CR269","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1056\/NEJM197112022852324","volume":"285","author":"G Scotti","year":"1971","unstructured":"Scotti G, Spinnler H (1971) Amantadine and Huntington\u2019s chorea. N Engl J Med 285:1325\u20131326. https:\/\/doi.org\/10.1056\/NEJM197112022852324","journal-title":"N Engl J Med"},{"key":"2306_CR270","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1179\/1743132812Y.0000000081","volume":"34","author":"V Shaygannejad","year":"2012","unstructured":"Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H (2012) Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurol Res 34:854\u2013858. https:\/\/doi.org\/10.1179\/1743132812Y.0000000081","journal-title":"Neurol Res"},{"key":"2306_CR271","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133398","author":"W Shen","year":"2020","unstructured":"Shen W et al (2020) Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine. J Clin Investig. https:\/\/doi.org\/10.1172\/JCI133398","journal-title":"J Clin Investig"},{"key":"2306_CR272","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1098\/rstb.2002.1161","volume":"357","author":"SM Sherman","year":"2002","unstructured":"Sherman SM, Guillery RW (2002) The role of the thalamus in the flow of information to the cortex. Philos Trans R Soc Lond B Biol Sci 357:1695\u20131708. https:\/\/doi.org\/10.1098\/rstb.2002.1161","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2306_CR273","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1212\/wnl.35.4.579","volume":"35","author":"WD Shields","year":"1985","unstructured":"Shields WD, Lake JL, Chugani HT (1985) Amantadine in the treatment of refractory epilepsy in childhood: an open trial in 10 patients. Neurology 35:579\u2013581. https:\/\/doi.org\/10.1212\/wnl.35.4.579","journal-title":"Neurology"},{"key":"2306_CR274","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00004714-199502000-00014","volume":"15","author":"RK Shrivastava","year":"1995","unstructured":"Shrivastava RK, Shrivastava S, Overweg N, Schmitt M (1995) Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors [letter]. J Clin Psychopharmacol 15:83\u201384","journal-title":"J Clin Psychopharmacol"},{"key":"2306_CR275","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00004714-198101000-00002","volume":"1","author":"LJ Siever","year":"1981","unstructured":"Siever LJ (1981) The effect of amantadine on prolactin levels and galactorrhea on neuroleptic-treated patients. J Clin Psychopharmacol 1:2\u20137. https:\/\/doi.org\/10.1097\/00004714-198101000-00002","journal-title":"J Clin Psychopharmacol"},{"key":"2306_CR276","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00004850-200511000-00007","volume":"20","author":"H Silver","year":"2005","unstructured":"Silver H, Goodman C, Isakov V, Knoll G, Modai I (2005) A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol 20:319\u2013326","journal-title":"Int Clin Psychopharmacol"},{"key":"2306_CR277","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.2042-7158.1970.tb10567.x","volume":"22","author":"J Simon","year":"1970","unstructured":"Simon J, Boissier JR (1970) Antagonism by amantadine of prochlorpemazine-induced catalepsy. J Pharm Pharmacol 22:546\u2013547","journal-title":"J Pharm Pharmacol"},{"key":"2306_CR278","first-page":"699","volume":"54","author":"G Skuza","year":"2002","unstructured":"Skuza G, Rogoz Z (2002) Effect of combined treatment with selective sigma ligands and amantadine in the forced swimming test in rats. Pol J Pharmacol 54:699\u2013702","journal-title":"Pol J Pharmacol"},{"key":"2306_CR279","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.pharep.2013.12.002","volume":"66","author":"G Skuza","year":"2014","unstructured":"Skuza G, Sadaj W, Kabzinski M, Cassano G, Gasparre G, Abate C, Berardi F (2014) The effects of new sigma (sigma) receptor ligands, PB190 and PB212, in the models predictive of antidepressant activity. Pharmacol Rep PR 66:320\u2013324. https:\/\/doi.org\/10.1016\/j.pharep.2013.12.002","journal-title":"Pharmacol Rep PR"},{"key":"2306_CR280","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2020.106004","volume":"55","author":"SP Smieszek","year":"2020","unstructured":"Smieszek SP, Przychodzen BP, Polymeropoulos MH (2020) Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. Int J Antimicrob Agents 55:1\u20134. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106004","journal-title":"Int J Antimicrob Agents"},{"issue":"Pt 1","key":"2306_CR281","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1469-7793.1998.047bf.x","volume":"512","author":"AI Sobolevsky","year":"1998","unstructured":"Sobolevsky AI, Koshelev SG, Khodorov BI (1998) Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons. J Physiol (Lond) 512(Pt 1):47\u201360","journal-title":"J Physiol (Lond)"},{"key":"2306_CR282","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.neuropharm.2011.11.017","volume":"62","author":"C Sommerauer","year":"2012","unstructured":"Sommerauer C, Rebernik P, Reither H, Nanoff C, Pifl C (2012) The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine. Neuropharmacology 62:1708\u20131716. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.11.017","journal-title":"Neuropharmacology"},{"key":"2306_CR283","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1007\/s12035-018-1278-3","volume":"56","author":"AE Speck","year":"2019","unstructured":"Speck AE, Schamne MG, Aguiar AJS, Cunha RA, Prediger RD (2019) Treadmill exercise attenuates l-DOPA-induced dyskinesia and increases striatal levels of glial cell-derived neurotrophic factor (GDNF) in Hemiparkinsonian. Mice Mol Neurobiol 56:2944\u20132951. https:\/\/doi.org\/10.1007\/s12035-018-1278-3","journal-title":"Mice Mol Neurobiol"},{"key":"2306_CR284","doi-asserted-by":"publisher","first-page":"244","DOI":"10.17221\/7884-VETMED","volume":"46","author":"J Stanicova","year":"2001","unstructured":"Stanicova J, Miskovsky P, Sutiak V (2001) Amantadine: an antiviral and antiparkinsonian agent. Vet Med Czech 46:244\u2013256","journal-title":"Vet Med Czech"},{"key":"2306_CR285","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051082","author":"M Stark","year":"2020","unstructured":"Stark M, Silva TFD, Levin G, Machuqueiro M, Assaraf YG (2020) The lysosomotropic activity of hydrophobic weak base drugs is mediated via their intercalation into the lysosomal membrane. Cells. https:\/\/doi.org\/10.3390\/cells9051082","journal-title":"Cells"},{"key":"2306_CR286","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF02252961","volume":"9","author":"MS Starr","year":"1995","unstructured":"Starr MS, Starr BS (1995) Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist. J Neural Transm Parkinsons Dis Dement Sect 9:31\u201343","journal-title":"J Neural Transm Parkinsons Dis Dement Sect"},{"key":"2306_CR287","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s004300050064","volume":"186","author":"L Stitz","year":"1998","unstructured":"Stitz L, Planz O, Bilzer T (1998) Lack of antiviral effect of amantadine in Borna disease virus infection. Med Microbiol Immunol (Berl) 186:195\u2013200","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"2306_CR288","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0014-2999(92)90634-G","volume":"213","author":"JC Stoof","year":"1992","unstructured":"Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-Parkinsonian drug amantadine inhibits the N-methyl-d-Aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213:439\u2013443","journal-title":"Eur J Pharmacol"},{"key":"2306_CR289","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00004850-200303000-00005","volume":"18","author":"R Stryjer","year":"2003","unstructured":"Stryjer R et al (2003) Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 18:93\u201396. https:\/\/doi.org\/10.1097\/00004850-200303000-00005","journal-title":"Int Clin Psychopharmacol"},{"key":"2306_CR290","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/WNF.0000000000000029","volume":"37","author":"R Stryjer","year":"2014","unstructured":"Stryjer R, Budnik D, Ebert T, Green T, Polak L, Weizman S, Spivak B (2014) Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study. Clin Neuropharmacol 37:79\u201381. https:\/\/doi.org\/10.1097\/WNF.0000000000000029","journal-title":"Clin Neuropharmacol"},{"key":"2306_CR291","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jneuroim.2013.05.006","volume":"261","author":"G Sulkowski","year":"2013","unstructured":"Sulkowski G, Dabrowska-Bouta B, Chalimoniuk M, Struzynska L (2013) Effects of antagonists of glutamate receptors on pro-inflammatory cytokines in the brain cortex of rats subjected to experimental autoimmune encephalomyelitis. J Neuroimmunol 261:67\u201376. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.05.006","journal-title":"J Neuroimmunol"},{"key":"2306_CR292","doi-asserted-by":"publisher","first-page":"e113954","DOI":"10.1371\/journal.pone.0113954","volume":"9","author":"G Sulkowski","year":"2014","unstructured":"Sulkowski G, Dabrowska-Bouta B, Salinska E, Struzynska L (2014) Modulation of glutamate transport and receptor binding by glutamate receptor antagonists in EAE rat brain. PLoS ONE 9:e113954. https:\/\/doi.org\/10.1371\/journal.pone.0113954","journal-title":"PLoS ONE"},{"key":"2306_CR293","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.2042-7158.1970.tb10592.x","volume":"22","author":"TH Svensson","year":"1970","unstructured":"Svensson TH, Stromberg U (1970) Potentiation by amantadine hydrochloride of l-dopa-induced effects in mice. J Pharm Pharmacol 22:639\u2013640. https:\/\/doi.org\/10.1111\/j.2042-7158.1970.tb10592.x","journal-title":"J Pharm Pharmacol"},{"key":"2306_CR294","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0361-9230(96)00211-0","volume":"41","author":"T Takahashi","year":"1996","unstructured":"Takahashi T, Yamashita H, Zhang YX, Nakamura S (1996) Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull 41:363\u2013367","journal-title":"Brain Res Bull"},{"key":"2306_CR295","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bbr.2014.10.037","volume":"279","author":"L Tan","year":"2015","unstructured":"Tan L et al (2015) Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats. Behav Brain Res 279:274\u2013282. https:\/\/doi.org\/10.1016\/j.bbr.2014.10.037","journal-title":"Behav Brain Res"},{"key":"2306_CR296","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.chembiol.2005.01.006","volume":"12","author":"JA Tanner","year":"2005","unstructured":"Tanner JA et al (2005) The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol 12:303\u2013311. https:\/\/doi.org\/10.1016\/j.chembiol.2005.01.006","journal-title":"Chem Biol"},{"key":"2306_CR297","doi-asserted-by":"publisher","first-page":"15219","DOI":"10.1021\/jacs.8b06741","volume":"140","author":"JL Thomaston","year":"2018","unstructured":"Thomaston JL, Polizzi NF, Konstantinidi A, Wang J, Kolocouris A, DeGrado WF (2018) Inhibitors of the M2 proton channel engage and disrupt transmembrane networks of hydrogen-bonded waters. J Am Chem Soc 140:15219\u201315226. https:\/\/doi.org\/10.1021\/jacs.8b06741","journal-title":"J Am Chem Soc"},{"key":"2306_CR298","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1517\/14728222.11.4.527","volume":"11","author":"AJ Thompson","year":"2007","unstructured":"Thompson AJ, Lummis SC (2007) The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 11:527\u2013540","journal-title":"Expert Opin Ther Targets"},{"key":"2306_CR299","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s0304-3940(01)02209-1","volume":"312","author":"TL Thompson","year":"2001","unstructured":"Thompson TL, Bridges S, Miller C (2001) Modulation of dopamine uptake in rat nucleus accumbens: effect of specific dopamine receptor antagonists and sigma ligands. Neurosci Lett 312:169\u2013172. https:\/\/doi.org\/10.1016\/s0304-3940(01)02209-1","journal-title":"Neurosci Lett"},{"key":"2306_CR300","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5603\/PJNNS.a2020.0039","volume":"54","author":"PW Tipton","year":"2020","unstructured":"Tipton PW, Wszolek ZK (2020) What can Parkinson\u2019s disease teach us about COVID-19? Neurol Neurochir Pol 54:204\u2013206. https:\/\/doi.org\/10.5603\/PJNNS.a2020.0039","journal-title":"Neurol Neurochir Pol"},{"key":"2306_CR301","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2174\/1381612820666140826113731","volume":"21","author":"DJ Titus","year":"2014","unstructured":"Titus DJ, Oliva AA, Wilson NM, Atkins CM (2014) Phosphodiesterase inhibitors as therapeutics for traumatic brain injury. Curr Pharm Des 21:332\u2013342. https:\/\/doi.org\/10.2174\/1381612820666140826113731","journal-title":"Curr Pharm Des"},{"key":"2306_CR302","first-page":"14","volume":"1","author":"Y Tizabi","year":"2017","unstructured":"Tizabi Y, Getachew B (2017) Nicotinic receptor intervention in Parkinson\u2019s disease: future directions. Clin Pharmacol Transl Med 1:14\u201319","journal-title":"Clin Pharmacol Transl Med"},{"key":"2306_CR303","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2003.11.005","volume":"218","author":"V Tomassini","year":"2004","unstructured":"Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C (2004) Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 218:103\u2013108. https:\/\/doi.org\/10.1016\/j.jns.2003.11.005","journal-title":"J Neurol Sci"},{"key":"2306_CR304","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0014-2999(95)00504-E","volume":"285","author":"S Tomitaka","year":"1995","unstructured":"Tomitaka S, Hashimoto K, Narita N, Minabe Y, Tamura A (1995) Amantadine induces c-fos in rat striatum: reversal with dopamine d-1 and NMDA receptor antagonists. Eur J Pharmacol 285:207\u2013211","journal-title":"Eur J Pharmacol"},{"key":"2306_CR305","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1110\/ps.062730007","volume":"16","author":"J Torres","year":"2007","unstructured":"Torres J, Maheswari U, Parthasarathy K, Ng L, Liu DX, Gong X (2007) Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein Sci 16:2065\u20132071. https:\/\/doi.org\/10.1110\/ps.062730007","journal-title":"Protein Sci"},{"key":"2306_CR306","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1515\/revneuro-2016-0063","volume":"28","author":"AS Tsybko","year":"2017","unstructured":"Tsybko AS, Ilchibaeva TV, Popova NK (2017) Role of glial cell line-derived neurotrophic factor in the pathogenesis and treatment of mood disorders. Rev Neurosci 28:219\u2013233. https:\/\/doi.org\/10.1515\/revneuro-2016-0063","journal-title":"Rev Neurosci"},{"issue":"Suppl. 4","key":"2306_CR307","first-page":"S235","volume":"20","author":"RJ Uitti","year":"1993","unstructured":"Uitti RJ et al (1993) Amantadine treatment is an independent predictor of improved survival in parkinsonism. Can J Neurol Sci 20(Suppl. 4):S235","journal-title":"Can J Neurol Sci"},{"key":"2306_CR308","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/WNL.46.6.1551","volume":"46","author":"RJ Uitti","year":"1996","unstructured":"Uitti RJ et al (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson\u2019s disease. Neurology 46:1551\u20131556","journal-title":"Neurology"},{"key":"2306_CR309","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0140-6736(71)90153-X","volume":"2","author":"S Vale","year":"1971","unstructured":"Vale S, Espejel MA, Dominguez JC (1971) Amantadine in depression. Lancet 2:437","journal-title":"Lancet"},{"key":"2306_CR310","first-page":"355","volume":"21","author":"A Valevski","year":"1998","unstructured":"Valevski A, Modal I, Zbarski E, Zemishlany Z, Weizman A (1998) Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients. Clin Neuropharmacol 21:355\u2013357","journal-title":"Clin Neuropharmacol"},{"key":"2306_CR311","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pmrj.2009.10.010","volume":"2","author":"JN Vargus-Adams","year":"2010","unstructured":"Vargus-Adams JN, McMahon MA, Michaud LJ, Bean J, Vinks AA (2010) Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. PM R 2:37\u201342. https:\/\/doi.org\/10.1016\/j.pmrj.2009.10.010","journal-title":"PM R"},{"key":"2306_CR312","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1212\/wnl.50.5.1323","volume":"50","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50:1323\u20131326. https:\/\/doi.org\/10.1212\/wnl.50.5.1323","journal-title":"Neurology"},{"key":"2306_CR313","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1212\/WNL.59.5.694","volume":"59","author":"L Verhagen Metman","year":"2002","unstructured":"Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN (2002) Huntington\u2019s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 59:694\u2013699","journal-title":"Neurology"},{"key":"2306_CR314","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/0041-008x(69)90066-0","volume":"15","author":"VG Vernier","year":"1969","unstructured":"Vernier VG, Harmon JB, Stump JM, Lynes TE, Marvel JP, Smith DH (1969) The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol Appl Pharmacol 15:642\u2013665. https:\/\/doi.org\/10.1016\/0041-008x(69)90066-0","journal-title":"Toxicol Appl Pharmacol"},{"key":"2306_CR315","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.174.4007.408","volume":"174","author":"PF Von Voigtlander","year":"1971","unstructured":"Von Voigtlander PF, Moore KE (1971) Dopamine: release from the brain in vivo by amantadine. Science 174:408\u2013410. https:\/\/doi.org\/10.1126\/science.174.4007.408","journal-title":"Science"},{"key":"2306_CR316","first-page":"542","volume":"184","author":"PF von Voigtlander","year":"1973","unstructured":"von Voigtlander PF, Moore KE (1973) Involvement of nigro-striatal neurons in the in vivo release of dopamine by amphetamine, amantadine and tyramine. J Pharmacol Exp Ther 184:542\u2013552","journal-title":"J Pharmacol Exp Ther"},{"key":"2306_CR317","doi-asserted-by":"publisher","first-page":"112432","DOI":"10.1016\/j.bbr.2019.112432","volume":"380","author":"V Walia","year":"2020","unstructured":"Walia V, Garg C, Garg M (2020) Amantadine exerts anxiolytic like effect in mice: evidences for the involvement of nitrergic and GABAergic signaling pathways. Behav Brain Res 380:112432. https:\/\/doi.org\/10.1016\/j.bbr.2019.112432","journal-title":"Behav Brain Res"},{"key":"2306_CR318","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0165-5728(99)00093-4","volume":"98","author":"KP Wandinger","year":"1999","unstructured":"Wandinger KP, Hagenah JM, Kluter H, Rothermundt M, Peters M, Vieregge P (1999) Effects of amantadine treatment on in vitro production of interleukin-2 in de-novo patients with idiopathic Parkinson\u2019s disease. J Neuroimmunol 98:214\u2013220","journal-title":"J Neuroimmunol"},{"key":"2306_CR319","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1128\/jvi.67.9.5585-5594.1993","volume":"67","author":"C Wang","year":"1993","unstructured":"Wang C, Takeuchi K, Pinto LH, Lamb RA (1993) Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 67:5585\u20135594","journal-title":"J Virol"},{"key":"2306_CR320","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1089\/neu.2013.2917","volume":"31","author":"T Wang","year":"2014","unstructured":"Wang T, Huang XJ, Van KC, Went GT, Nguyen JT, Lyeth BG (2014) Amantadine improves cognitive outcome and increases neuronal survival after fluid percussion traumatic brain injury in rats. J Neurotrauma 31:370\u2013377. https:\/\/doi.org\/10.1089\/neu.2013.2917","journal-title":"J Neurotrauma"},{"key":"2306_CR321","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1056\/NEJM197201132860220","volume":"286","author":"WJ Weiner","year":"1972","unstructured":"Weiner WJ, Klawans HL Jr (1972) Amantadine in Huntington\u2019s chorea. N Engl J Med 286:106. https:\/\/doi.org\/10.1056\/NEJM197201132860220","journal-title":"N Engl J Med"},{"key":"2306_CR322","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-2999(94)00718-m","volume":"275","author":"SD Weiser","year":"1995","unstructured":"Weiser SD et al (1995) Stimulation of rat striatal tyrosine hydroxylase activity following intranigral administration of sigma receptor ligands. Eur J Pharmacol 275:1\u20137. https:\/\/doi.org\/10.1016\/0014-2999(94)00718-m","journal-title":"Eur J Pharmacol"},{"key":"2306_CR323","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0006-8993(93)90464-X","volume":"613","author":"M Weller","year":"1993","unstructured":"Weller M, Finielsmarlier F, Paul SM (1993) NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons\u2014neuroprotective properties of amantadine and memantine. Brain Res 613:143\u2013148","journal-title":"Brain Res"},{"key":"2306_CR324","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0926-6917(95)00028-3","volume":"293","author":"GL Wenk","year":"1995","unstructured":"Wenk GL, Danysz W, Mobley SL (1995) MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 293:267\u2013270","journal-title":"Eur J Pharmacol"},{"key":"2306_CR325","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/00001756-199606170-00001","volume":"7","author":"GL Wenk","year":"1996","unstructured":"Wenk GL, Danysz W, Roice DD (1996) The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. NeuroReport 7:1453\u20131456","journal-title":"NeuroReport"},{"key":"2306_CR326","first-page":"1241","volume":"32","author":"W Wesemann","year":"1982","unstructured":"Wesemann W, Ekenna O (1982) Effect of 1-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzneimittel Forschung Drug Res 32:1241\u20131243","journal-title":"Arzneimittel Forschung Drug Res"},{"key":"2306_CR327","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF01250322","volume":"44","author":"W Wesemann","year":"1979","unstructured":"Wesemann W, Dette-Wildenhahn G, Fellehner H (1979) In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson J Neural Transm 44:263\u2013285","journal-title":"Parkinson J Neural Transm"},{"key":"2306_CR328","first-page":"1122","volume":"33","author":"W Wesemann","year":"1983","unstructured":"Wesemann W, Sontag K-H, Maj J (1983) Zur Pharmakodynamik und Pharmakokinetik des Memantin Arzneimittel. Forschung Drug Res 33:1122\u20131132","journal-title":"Forschung Drug Res"},{"key":"2306_CR329","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.apmr.2004.05.016","volume":"86","author":"J Whyte","year":"2005","unstructured":"Whyte J et al (2005) Predictors of outcome in prolonged posttraumatic disorders of consciousness and assessment of medication effects: a multicenter study. Arch Phys Med Rehabil 86:453\u2013462. https:\/\/doi.org\/10.1016\/j.apmr.2004.05.016","journal-title":"Arch Phys Med Rehabil"},{"key":"2306_CR330","unstructured":"Wikipedia (2020) Bob Beamon. https:\/\/en.wikipedia.org\/wiki\/Bob_Beamon"},{"key":"2306_CR331","doi-asserted-by":"publisher","DOI":"10.3389\/fnsys.2016.00005","author":"NM Wilson","year":"2016","unstructured":"Wilson NM, Titus DJ, Oliva AA, Furones C, Atkins CM (2016) Traumatic brain injury upregulates phosphodiesterase expression in the hippocampus. Front Syst Neurosci. https:\/\/doi.org\/10.3389\/fnsys.2016.00005","journal-title":"Front Syst Neurosci"},{"key":"2306_CR332","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1345\/aph.17428","volume":"32","author":"ST Woodrum","year":"1998","unstructured":"Woodrum ST, Brown CS (1998) Management of SSRI-induced sexual dysfunction. Ann Pharmacother 32:1209\u20131215","journal-title":"Ann Pharmacother"},{"key":"2306_CR333","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jemermed.2004.11.016","volume":"28","author":"TS Wu","year":"2005","unstructured":"Wu TS, Garmel GM (2005) Improved neurological function after Amantadine treatment in two patients with brain injury. J Emerg Med 28:289\u2013292. https:\/\/doi.org\/10.1016\/j.jemermed.2004.11.016","journal-title":"J Emerg Med"},{"key":"2306_CR334","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jns.2017.07.042","volume":"380","author":"TT Yang","year":"2017","unstructured":"Yang TT, Wang L, Deng XY, Yu G (2017) Pharmacological treatments for fatigue in patients with multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci 380:256\u2013261. https:\/\/doi.org\/10.1016\/j.jns.2017.07.042","journal-title":"J Neurol Sci"},{"key":"2306_CR335","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3109\/10253890.2015.1108302","volume":"19","author":"M Yu","year":"2016","unstructured":"Yu M, Zhang Y, Chen X, Zhang T (2016) Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress. Stress 19:104\u2013113. https:\/\/doi.org\/10.3109\/10253890.2015.1108302","journal-title":"Stress"},{"key":"2306_CR336","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/026990598122386","volume":"12","author":"RD Zafonte","year":"1998","unstructured":"Zafonte RD, Watanabe T, Mann NR (1998) Amantadine\u202f: a potential treatment for the minimally conscious state. Brain Inj 12:617\u2013621","journal-title":"Brain Inj"},{"key":"2306_CR337","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/00001199-200102000-00014","volume":"16","author":"RD Zafonte","year":"2001","unstructured":"Zafonte RD, Lexell J, Cullen N (2001) Possible applications for dopaminergic agents following traumatic brain injury: part 2. J Head Trauma Rehabil 16:112\u2013116. https:\/\/doi.org\/10.1097\/00001199-200102000-00014","journal-title":"J Head Trauma Rehabil"},{"key":"2306_CR338","doi-asserted-by":"publisher","first-page":"e24998","DOI":"10.5812\/ircmj.24998","volume":"17","author":"A Zahiroddin","year":"2015","unstructured":"Zahiroddin A, Faridhosseini F, Zamani A, Shahini N (2015) Comparing the efficacy of bupropion and amantadine on sexual dysfunction induced by a selective serotonin reuptake inhibitor Iran. Red Crescent Med J 17:e24998. https:\/\/doi.org\/10.5812\/ircmj.24998","journal-title":"Red Crescent Med J"},{"key":"2306_CR339","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/brain\/124.7.1263","volume":"124","author":"A Zeman","year":"2001","unstructured":"Zeman A (2001) Consciousness. Brain 124:1263\u20131289. https:\/\/doi.org\/10.1093\/brain\/124.7.1263","journal-title":"Brain"},{"key":"2306_CR340","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/ALN.0000000000000352","volume":"121","author":"J Zhang","year":"2014","unstructured":"Zhang J, Tan H, Jiang W, Zuo Z (2014) Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats. Anesthesiology 121:773\u2013785. https:\/\/doi.org\/10.1097\/ALN.0000000000000352","journal-title":"Anesthesiology"},{"key":"2306_CR341","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/JCP.0000000000000598","volume":"37","author":"W Zheng","year":"2017","unstructured":"Zheng W et al (2017) Amantadine for antipsychotic-related weight gain: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 37:341\u2013346. https:\/\/doi.org\/10.1097\/JCP.0000000000000598","journal-title":"J Clin Psychopharmacol"},{"key":"2306_CR342","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.605330","author":"J Zhong","year":"2020","unstructured":"Zhong J, Li J, Ni C, Zuo Z (2020) Amantadine alleviates postoperative cognitive dysfunction possibly by preserving neurotrophic factor expression and dendritic arborization in the hippocampus of old rodents. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2020.605330","journal-title":"Front Aging Neurosci"},{"key":"2306_CR343","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/02791072.1991.10471612","volume":"23","author":"DM Ziedonis","year":"1991","unstructured":"Ziedonis DM, Kosten TR (1991) Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J Psychoact Drugs 23:417\u2013425. https:\/\/doi.org\/10.1080\/02791072.1991.10471612","journal-title":"J Psychoact Drugs"},{"key":"2306_CR344","volume-title":"Periodic safety update report for PK-Merz active: amantadine sulphate. Report","author":"M Zimmermann","year":"1997","unstructured":"Zimmermann M (1997) Periodic safety update report for PK-Merz active: amantadine sulphate. Report. Merz Pharmaceuticals, Frankfurt"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-021-02306-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-021-02306-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-021-02306-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T09:10:17Z","timestamp":1674983417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-021-02306-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":343,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2306"],"URL":"https:\/\/doi.org\/10.1007\/s00702-021-02306-2","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"22 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}